VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24105GJ1982PLC005057

Date: 19th August, 2026

To,
Department of Corporate Services,
BSE Limited,
Ground Floor, P. J. Towers,
Dalal Street,
Mumbai – 400001,

Scrip Code: 530057 **ISIN: INE984E01035**

Subject: Notice of the 44th Annual General Meeting ('AGM') and Annual Report of the Company for the Financial Year 2025-26

Dear Sir/Madam,

We wish to inform you that 44th AGM of the Company is scheduled to be held on Friday, September 11, 2026, at 03:30 P.M. (IST) through Video Conference/Other Audio Visual Means.

Pursuant to Regulation 34 and Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), please find enclosed the Notice of the 44th AGM and Annual Report of the Company which are being sent in electronic mode to the shareholders of the Company whose e-mail addresses are registered with the Company/ Registrar & Share Transfer Agent/ Depositories.

For those shareholders who have not registered their email addresses, a letter providing the weblink from which the Notice of the 44th AGM and Annual Report for the financial year 2025-26 can be accessed is being sent.

The Notice will also be made available on the Company's website at www.vivanzabiosciences.com.

We request you to take the same on record.

Thanking you

For Vivanza Biosciences Limited

JAYENDRA AMICHAND MEHTA

Digitally signed by JAYENDRA AMICHAND MEHTA
Date: 2026.08.19 11:35:29 +05'30'

JAYENDRA MEHTA
MANAGING DIRECTOR
DIN: 08210602

VIVANZA™
BIOSCIENCES LTD.

BUILDING A
HEALTHIER TOMORROW
FOR EVERY LIFE,
EVERYWHERE.

ANNUAL REPORT 2025-26

Science • Compassion • Impact

Discover Secrets of ***Long & Healthy Life*** *to Improving the* ***lives of people*** *globally*

INNOVATION
Pioneering discoveries for a better tomorrow

RESEARCH EXCELLENCE
Advanced science driving meaningful impact

TRUST & QUALITY
Uncompromising standards for global trust

GLOBAL IMPACT
Touching lives across communities worldwide

Together, we **advance life.**

www.vivanzabiosciences.com

Disclaimer: Product images are for illustration purposes only. New products will be introduced soon.

SCIENCE DRIVEN HEALTH FOCUSED PATIENT CENTRIC QUALITY ASSURED

INSIDE DETAILS

INDEX

CORPORATE INFORMATION

BOARD OF DIRECTORS

Mr. Jayendra A. Mehta	:	Managing Director
Mr. Sarang B. Pathak	:	Non Executive Non Independent Director (Appointed w.e.f. 30.08.2025)
Mr. Parikh H. A.	:	Non Executive Non Independent Additional Director (Appointed w.e.f. 18.06.2026)
Ms. Rina Kumari	:	Independent Director
Mr. Hitesh Rijwani	:	Independent Director (Appointed w.e.f 12.05.2025)

KEY MANAGERIAL PERSONNEL

Mr. Jainil R. Bhatt	:	Chief Financial Officer
Mr. Chaitra Arora	:	Company Secretary (Resigned w.e.f 30.04.2026)
Mr. Vishal Katarmal	:	Company Secretary (appointed w.e.f 08.07.2026)

AUDITOR

Shivam Soni & Co.
Chartered Accountants
Ahmedabad

SECRETARIAL AUDITOR

M/s. Chintan Patel & Associates,
Practicing Company Secretary
Ahmedabad.

REGISTERED OFFICE

403/TF, Sarthik II, Opp. Rajpath Club, S.G Highway, Bodakdev, Ahmedabad
CIN:L24105GJ1982PLC005057
Email: info@vivanzabiosciences.com
Website: www.vivanzabiosciences.com

REGISTRAR & SHARE TRANSFER AGENTS

Purva Sharegistry (India) Pvt. Ltd.
Shiv Shakti Industrial Estates,
Unit No. 9 J. R. Boricha Marg,
Opp. Kasturba Hospital Lane
Lower Parel (E), Mumbai –400011
Email: support@purvashare.com

STOCK CODE

BSE: 530057
ISIN: INE984E01035

NOTICE

Notice is hereby given that the 44th Annual General Meeting of the Shareholders of **Vivanza Biosciences Limited**will be held on Friday, 11th September, 2026 at 03:30 P.M. through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) to transact the following business. The venue of the meeting shall be deemed to be the registered office of the Company at 403, Sarthik 2, Opp. Rajpath Club, S.G Highway, Ahmedabad-380054, Gujarat, India

ORDINARY BUSINESS:

1. **ADOPTION OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED MARCH 31ST, 2026 TOGETHER WITH THE REPORTS OF THE BOARD OF DIRECTORS AND INDEPENDENT AUDITOR'S REPORTS THEREON.**

   To consider and, if thought fit, to pass with or without modification(s), the following Resolution as an **Ordinary Resolution.**

"RESOLVED THAT:

a. The Audited Standalone Financial Statements of the Company for the Financial Year ended on 31st March, 2026 and reports of the Board of Directors and Independent Auditor's report thereon laid before this meeting, be and is hereby considered and adopted.

b. The Audited Consolidated Financial Statements of the Company for the Financial Year ended on 31st March, 2026 and reports of Board of Directors and Independent Auditor's report thereon laid before this meeting, be and is hereby considered and adopted.

2. **TO APPOINT A DIRECTOR IN PLACE OF MR. JAYENDRA MEHTA (DIN: 08210602) WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR RE-APPOINTMENT.**

   To consider, and if thought fit to pass the following resolution as an **Ordinary Resolution:**

   "RESOLVED THAT pursuant to the provisions of Section 152 and all other applicable provisions of the Companies Act, 2013 read with Rules framed thereunder (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), Mr. Jayendra A. Mehta (DIN: 08210602), Director, who retires by rotation at this 44th Annual General Meeting, and being eligible for re-appointment, be and is hereby re-appointed as a Director of the Company, liable to retire by rotation."

SPECIAL BUSINESS:

3. **TO APPROVE REGULARIZATION OF ADDITIONAL DIRECTOR MR. H.A PARIKH (DIN: 00027820) AS A NON-EXECUTIVE NON-INDEPENDENT DIRECTOR OF THE COMPANY.**

   To consider and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution:**

   "RESOLVED THAT, pursuant to the provisions of Section 149, 152, 160 and all other provisions of the Companies Act, 2013 and the Companies (Appointment and Qualifications of Directors) Rules, 2014, [including any statutory modification(s) or re-enactment(s) thereof for the time being in force] and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and other applicable laws Mr. H.A Parikh (DIN: 00027820), who was appointed as an Additional Director of the Company With effect from 18th June, 2026 by the Board of Directors pursuant to Section 161 of the Companies Act, 2013 and as recommended by Nomination &

Remuneration Committee and who holds office only upto Annual General Meeting to be held on September 11th, 2026 and for appointment of whom Notice under Rule 13 of Companies (Appointment and Qualifications of Directors) Rules, 2014 proposing his candidature for the office of Director has been received, be and is hereby appointed as Non-Executive, Non- Independent Director, whose period of office will be liable to determination by Retirement of directors Rotation."

"RESOLVED FURTHER THAT, the Board of Directors of the Company be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, desirable or expedient to give effect to this resolution."

4. TO APPROVE THE MATERIAL RELATED PARTY TRANSACTION(S) PROPOSED TO BE ENTERED INTO BY THE COMPANY DURING THE FINANCIAL YEAR 2026-2027.

To consider and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 188 and other applicable provisions, if any of the Companies Act, 2013 ("Act"), read with Rule 15 of the Companies (Meetings of Board and its Powers) Rules, 2014) and Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), including any statutory modification(s) or re-enactment thereof for the time being in force and subject to such approvals, consents, sanctions and permissions as may be necessary, if any, approval of the members be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the "Board" which term shall include any Committee constituted by the Board or any person(s) authorized by the Board to exercise its powers, including the powers conferred by this Resolution) to enter into contract(s)/ arrangement(s)/ transaction(s) with the parties as detailed in the **Annexure-A** forming part of the Explanatory Statement annexed to this notice with respect to sale, purchase or supply of goods or materials, leasing of property of any kind, availing or rendering of any services including the providing and/or receiving of loans or guarantees or securities or making investments, or any other transactions of whatever nature, notwithstanding that such transactions may exceed 10% of the consolidated turnover of the Company in any financial year or such other threshold limits as may be specified by the Listing Regulations from time to time, up to Rs. 100 Crore (One Hundred Crore only) on such terms and conditions as the Board of Directors may deem fit, in the normal course of business and on arm's length basis, during the period from the date of this Annual General Meeting till the date of next Annual General Meeting, which shall not be more than fifteen months and within the aggregate limits as mentioned in the explanatory statement.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to do or cause to be done all such acts, matters, deeds and things and to settle any queries, difficulties that may arise with regard to any transaction with the related party and execute such agreements, documents and writings and to make such filings as may be necessary or desirable for the purpose of giving effect to this resolution, in the best interest of the Company."

5. TO CONSIDER THE ADOPTION OF A NEW SET OF MEMORANDUM OF ASSOCIATION IN LINE WITH COMPANIES ACT, 2013:

To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution:**

"**RESOLVED THAT** pursuant to the provisions of Section 13 of the Companies Act, 2013 (the 'Act'), read with the Companies (Incorporation) Rules, 2014, and any other applicable provisions, (including any modification(s) thereto or re-enactment(s) thereof for the time being in force), the consent of the members be and is hereby accorded, to substitute the existing Memorandum of Association of the company and adopt new set of Memorandum of Association as per the provisions of the Companies Act, 2013."

"RESOLVED FURTHER THAT any one of the Directors of the Company be and is hereby authorized to do all such acts, deeds, matters, and things, including filing necessary forms with the Registrar of Companies, as may be deemed necessary, proper, or expedient to give effect to this resolution."

6. TO CONSIDER THE ADOPTION OF NEW SET OF ARTICLES OF ASSOCIATION IN LINE WITH COMPANIES ACT, 2013:

To consider and, if thought fit, to pass, with or without modification(s), the following resolution as **Special Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 14 of the Companies Act, 2013 (the 'Act'), read with the Companies (Incorporation) Rules, 2014, and any other applicable provisions, including any modification(s) thereto or re-enactment(s) thereof for the time being in force, the consent of the members be and is hereby accorded, to substitute the existing Articles of Association of the company and adopt new set of Articles of Association as per the provisions of the Companies Act, 2013 ."

"RESOLVED FURTHER THAT any one of the Director of the Company, be and is hereby authorized to do all such acts, deeds, matters, and things, including filing necessary forms with the Registrar of Companies, as may be deemed necessary, proper, or expedient to give effect to this resolution."

7. TO APPROVE INCREASE IN BORROWING LIMITS UNDER SECTION 180(1)(C) OF THE COMPANIES ACT, 2013 ("ACT")

To consider, and if thought fit, to pass with or without modification(s) the following Resolution(s) as a **Special Resolution:**

"RESOLVED THAT in supersession of all earlier resolution and pursuant to the provisions of Section 180(1)(c) and other applicable provisions, if any, of the Act and rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force), the Articles of Association ("AOA") of the Company and subject to such other approvals as may be necessary, , the consent of the Members of the Company be and is hereby accorded to the Board (which term shall be deemed to include any committee(s) thereof which the Board may hereinafter constitute to exercise its powers including the powers conferred pursuant to this Resolution') to borrow any sum or sums of money on such terms and conditions and with or without security, as the board of directors may think fit, from time to time, by obtaining loans, overdraft facilities, lines of credit, commercial papers, convertible/ non-convertible debentures, external commercial borrowings (loans/bonds), or in any other forms from Banks, Financial Institutions, other Bodies Corporate or other eligible investors, from time to time, which, together with the monies already borrowed by the Company and the monies to be borrowed (apart from temporary loans obtained or to be obtained from the Company's bankers in the ordinary course of business) may exceed, at any time, the aggregate of the paid-up share capital, free reserves and securities premium provided that the total amount so borrowed by the Board shall not at any time exceed Rs. 100 Crores (Rupees One Hundred crores only) or equivalent amount in any other foreign currency."

"RESOLVED FURTHER THAT the Board be and is/are hereby authorized to do such acts, deeds, things and execute all such documents, undertakings, as may be necessary, expedient or incidental for giving effect to the above Resolution."

8. **TO APPROVE INVESTMENTS, GIVE LOANS, GUARANTEES/LETTER OF COMFORT/LETTER OF SUPPORT AND SECURITY UNDER SECTION 186 OF THE ACT**

To consider, and if thought fit, to pass with or without modification the following Resolution(s) as a **Special Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 186 and other applicable provisions, if any, of the Act and relevant rules thereto including any statutory amendment or modifications thereto and in compliance with memorandum and articles of association and other applicable provisions, if any, and subject to such approvals, consents, sanctions and permissions, as may be necessary, consent of the Members of the Company be and is hereby accorded to the Board (which term shall include any Committee constituted by the Board or any person(s) authorized by the Board to exercise its powers, including the powers conferred by this Resolution) to (i) give any loan to any person or other body corporate; (ii) give any guarantee or provide security or letter of comfort or letter of support in connection with a loan to any person or other body corporate; and (iii) acquire by way of subscription, purchase or otherwise, securities of any other body corporate, from time to time, as the Board of Directors in their absolute discretion deem beneficial and in the interest of the Company, on such terms and conditions and with or without security, for an amount not exceeding INR 50 crores (Rupees Fifty crores only), notwithstanding that such investments, outstanding loans given or to be given and guarantees and security or letter of comfort or letter of security provided are in excess of the limits prescribed under Section 186 (2) of the Act. The Board of Directors is authorized to negotiate and decide from time to time, terms and conditions, execute necessary documents, papers, agreements etc. for guarantees to be given or letter of comfort or letter of security and/or securities to be provided to any person and / or anybody corporate, to do all such acts deeds, matters and things, as it may, in its absolute discretion, deem necessary, proper or desirable, settle any question, difficulty or doubt that may arise in this regard and to delegate all or any of these powers to a Director or any other person."

"RESOLVED FURTHER THAT the Board be and is/are hereby authorized to do such acts, deeds, things and execute all such documents, undertakings, as may be necessary, expedient or incidental for giving effect to the above Resolution."

9. **TO APPROVE ADVANCEMENT OF ANY LOAN / FINANCIAL ASSISTANCE /GIVE GUARANTEE/PROVIDE SECURITY/ LETTER OF COMFORT/LETTER OF SUPPORT UNDER SECTION 185 OF THE ACT IN WHICH DIRECTORS ARE INTERESTED**

To consider, and if thought fit, to pass with or without modification(s) the following Resolution(s) as **a Special Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 185 and other applicable provisions, if any of the Act (including any statutory modification(s) or re-enactment thereof for the time being in force) and subject to such approvals, consents, sanctions and permissions as may be necessary, approval of the Members be and is hereby accorded to the Board (which term shall include any committee constituted by the Board or any person(s) authorized by the Board to exercise its powers, including the powers conferred by this Resolution), for giving loan(s) in one or more tranches including loan represented by way of book debt (the "Loan") to, and/or giving of guarantee(s), and/or providing of security(ies) and/or letter of support/letter of comfort in connection with any Loan or financial assistance taken/to be taken/availed/to be availed by any entity, which is a subsidiary or associate or joint venture or group entity of the Company or any other entity/person specified under section 185 of the Act and more specifically to such other entity/person as the Board of Directors in its absolute discretion deems fit and beneficial and in the best interest of the Company (collectively referred to as the "Entities"), for an aggregate amount not exceeding INR 50 Crores (Rupees Fifty crores Only)."

"RESOLVED FURTHER THAT the abovementioned Loan and/or financial assistance and/or guarantee(s) and/or security(ies)/letter of support/letter of comfort shall only be utilized by the borrower for the purpose of its principal business activities."

"RESOLVED FURTHER THAT the Board be and is/are hereby authorized to do such acts, deeds, things and execute all such documents, undertakings, as may be necessary, expedient or incidental for giving effect to the above Resolution."

Date:August 17, 2026
Place: Ahmedabad

By order of the Board
For VIVANZA BIOSCIENCES LIMITED

Sd/-
Vishal Katarmal
(Company Secretary & Compliance Officer)

Notes:

1. Pursuant to General Circular No. 09/2023 dated September 25, 2023, in relation to "Clarification on passing of ordinary and special resolutions by companies under the Companies Act, 2013 and the rules made thereunder issued by the Ministry of Corporate Affairs, Government of India (collectively, referred to as the "MCA Circular"), the facility to appoint proxy to attend and cast vote for the members is not available for this AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and participate there at and cast their votes through e-voting. Institutional/Corporate Shareholders (i.e. other than individuals/HUF, NRI, etc) are required to send a scanned copy (PDF/JPEG Format) of its Board Resolution or governing body Resolution/Authorisation etc. authorising its representative to attend the Annual General Meeting through VC/OAVM on its behalf and to vote through remote e-voting. The said Resolution/Authorisation shall be sent to the Scrutinizer by email through their registered email address to cschintanpatel@gmail.com with copies marked to the Company at info@vivanzabiosciences.com.

   Further, Securities and Exchange Board of India (SEBI), vide its Circulars dated May 12, 2020, January 15, 2021, May 13, 2022, January 5, 2023, October 7, 2023 and October 3, 2024 (SEBI Circulars) and other applicable circulars issued in this regard, have provided relaxations from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

2. The deemed venue for 44th AGM shall be the registered office of the Company.

3. The explanatory statement pursuant to Section 102 of the Companies Act, 2013 ('the Act') with respect to the special businesses set out in the notice is annexed hereto and forms part of this notice.

4. Members are requested to participate on first come first served basis, as participation through VC/OAVM is limited. Members can login and join 15 (fifteen) minutes prior to the scheduled time of the commencement of the meeting and window for joining shall be kept open till the expiry of 15 (fifteen) minutes after the scheduled time. Participation is restricted upto 1000 members only. However, the participation of large shareholders (i.e. shareholders holding 2% or more shareholding), promoters, institutional investors, directors, key managerial personnel, the chairperson of the Audit committee, Nomination and remuneration committee and stakeholders Relationship committee, Auditors etc. will not be subject to restriction of first come first served basis.

5. Members holding shares in dematerialized form are requested to intimate all changes with respect to their address/bank details/mandate etc. to their respective Depository Participant. The Company or its share transfer agent will not act on any direct request from these members for change of such details. However, request for any change in respect of shares held in physical form should be sent to Company or Registrar & Share Transfer Agent.

6. Member seeking information are requested to send email at info@vivanzabiosciences.com.

7. The Ministry of Corporate Affairs ("MCA"), Government of India, has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by companies vide General Circular No. 09/2023 dated September 25, 2023, in relation to "Clarification on passing of ordinary and special resolutions by companies under the Companies Act, 2013 and the rules made thereunder issued by the Ministry of Corporate Affairs, Government of India (collectively, referred to as the "MCA Circular") respectively in terms of which a company would have ensured compliance with the provisions of Section 20 of the Companies Act 2013, if service of documents have been made through electronic mode. In such a case, the Company has to obtain e-mail addresses of its members for sending the

notices/documents through e-mail giving an advance opportunity to each shareholder to register their e-mail address and changes therein, if any, from time to time with the Company.

The Company has welcomed the Green Initiative and accordingly has e-mailed the soft copies of the Financial Statements for the financial year ended 31st March, 2026, to all those Members whose e-mail IDs are available with the Company's Registrar and Transfer Agent.

In view of the above, the Company hereby request members who have not updated their email IDs to update the same with their respective Depository Participant(s) or the Purva Sharegistry India Pvt. Ltd, Registrar and Transfer Agent (R&T) of the Company.

Further, members holding shares in electronic mode are also requested to ensure to keep their email addresses updated with the Depository Participants/R&T of the Company. Members holding shares in physical mode are also requested to update their email addresses by writing to the R &T of the Company quoting their folio number(s).

8. SEBI vide its notification dated 08/06/2018 has mandated that, except in case of transmission or transposition of securities, requests for effecting transfer of securities shall not be processed unless the securities are held in the dematerialized form with a depository. Members holding shares in physical form are therefore requested to dematerialize their share certificates. In compliance with provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 substituted by the Companies (Management and Administration) Amendment Rule, 2015 and Regulation 44 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , the Company is pleased to provide members facility to exercise their right to vote at the 44th Annual General Meeting (AGM) by electronic means and the business may be transacted through e-Voting Services provided by National Securities Depository Limited (NSDL). The detailed process, instructions and manner for e-voting facility is enclosed herewith. Members if the Company holding shares either in the physical form or in Dematerialized form, as on cut-off date i.e. Friday, 04th September, 2026 may cast their vote by electronic means or in the AGM.

9. The detailed process instruction and manner for e-voting facility is enclosed herewith.

10. The Members who have casted their vote by remote e-voting may also attend the AGM, but shall not be entitled to cast their vote again.

11. The remote e-Voting period commences on Tuesday, 08th September, 2026 (9:00 a.m.) and ends on Thursday, 10th September, 2026 (5:00 p.m.). during this period, Members holding shares either in physical form or demat form, as on Friday, 04th September, 2026 i.e. cut-off date, may cast their vote electronically. The e-voting module shall be disabled for voting thereafter. Once the vote on a resolution is cast by the Member, he/she shall not be allowed to change it subsequently or cast vote again.

12. The voting rights of Members shall be in proportion to their shares in the paid-up equity share capital of the Company as on cut-off date. A person, whose names is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on cut-off date only shall be entitled to avail facility of remote e-voting and e-voting at AGM.

13. Any person, who acquires shares of the Company and becomes a Member of the Company after dispatch of the Notice and holding shares as on cut-off date, may cast vote after following the instructions for e-voting as provided in the Notice convening the Meeting, which is available on the website of the Company and NSDL. However, if you are already registered with NSDL for remote e-voting then you can use your existing User ID and password for casting your vote.

14. The Board of Directors has appointed Mr. Chintan Patel, Practicing Company Secretary as a Scrutinizer to scrutinize the e-voting at AGM and remote e-voting process in a fair and transparent manner.

15. The Scrutinizer shall, immediately after the conclusion of voting at the meeting, would count the votes cast at the meeting, thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and make, not later than two days of conclusion of the meeting, a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman, who shall countersign the same.

16. The results to be declared along with the Scrutinizer's Report shall be placed on the Company's website www.vivanzabiosciences.com and on the website of NSDLwww.evoting.nsdl.com immediately after the result is declared. The Company shall simultaneously forward the results to BSE Limited [BSE] where the equity shares of the Company are listed.

17. The relevant details as required under Regulation 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with clause 1.2.5 of Secretarial Standards-2 of persons seeking appointment/reappointment as a Director of the notice are also annexed to the notice.

NSDL e-Voting System– For e-voting and Joining Virtual meetings.

1. Pursuant to the General Circular No. 09/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs (MCA) and circular issued by SEBI vide circular no. SEBI/ HO/ CFD/ CFDPoD-2/ P/ CIR/ 2024/ 133 dated October 3, 2024 ("SEBI Circular") and other applicable circulars and notifications issued (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time, companies are allowed to hold EGM/AGM through Video Conferencing (VC) or other audio visual means (OAVM), without the physical presence of members at a common venue. In compliance with the said Circulars, EGM/AGM shall be conducted through VC / OAVM.

2. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this EGM/AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the EGM/AGM through VC/OAVM and participate there at and cast their votes through e-voting.

3. The Members can join the EGM/AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the EGM/AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the EGM/AGM without restriction on account of first come first served basis.

4. The attendance of the Members attending the EGM/AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) the Secret arial Standard on General Meetings (SS-2) issued by the ICSI and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs from time to time the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the EGM/AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic

means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the EGM/AGM will be provided by NSDL.

6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the EGM/AGM has been uploaded on the website of the Company at www.vivanzabiosciences.com. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and the EGM/AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

7. EGM/AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular issued from time to time

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

The remote e-voting period begins on Tuesday 08th September, 2026 at 09:00 A.M. and ends on Thursday 10th September, 2026 at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. 04th September, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being 04th September, 2026.

How do I vote electronically using NSDL e-Voting system?
The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:
Step 1: Access to NSDL e-Voting system
A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode
In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.
Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner"** icon under **"Login"** which is available under **'IDeAS'**section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on **"Access to e-Voting"** under e-Voting services and you will be able to see e-Voting page. Click

<table>
<tr><td></td><td>on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS Portal” or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp
4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
5. Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.

</td></tr>
<tr><td>Individual Shareholders holding securities in demat mode with CDSL</td><td>1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password.
2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers’ website directly.
3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option.
4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account.</td></tr>
</table>

	After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.

b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
   c) How to retrieve your 'initial password'?
   (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
   (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
   a) Click on "**Forgot User Details/Password**?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
   b) **Physical User Reset Password**?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail tocschintanpatel@gmail.comwith a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “Forgot User Details/Password?” or “Physical User Reset Password?” option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request atevoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email info@vivanzabiosciences.com.
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to (info@vivanzabiosciences.com). If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A**) i.e. **Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**.
3. Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE EGM/AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the EGM/AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the EGM/AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the EGM/AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the EGM/AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the EGM/AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE EGM/AGM THROUGHVC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM" placed under **"Join meeting"** menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at (info@vivanzabiosciences.com). The same will be replied by the company suitably.

6. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast 10 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at info@vivanzabiosciences.com. The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 10 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.

7. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 IN RESPECT OF SPECIAL BUSINESSES SET OUT IN THE NOTICE.

As required under Section 102 of the Companies Act, 2013 (including any statutory modifications thereto or re-enactments made thereunder, if any, for the time being in force (the "Act"), the following explanatory statement sets out all material facts relating to the business mentioned in the accompanying Notice:

ITEM NO. 2

Details of Directors seeking Appointment/ Re-appointment at the AGM

Name of the Director	Mr. Jayendra A. Mehta
Date of Birth	01/06/1965
Nationality	Indian
Date of Initial Appointment	25.04.2023
Qualifications	F.Y.B.COM
Experience and Expertise in specific functional area	Having 25+ Years of rich experience in business management along with expertise in legal matters.
No. of Board Meeting attended during the year	5 (Five)
Number of shares held in the Company	NIL
Designation	Managing Director
Other directorships held including in listed entity	1. Vitaaglobal Bioscience Private Limited - Director 2. Vaishali Lifecare Private Limited - Director 3. Vital I.P. Private limited - Director 4. Vital Intelligence Technology Private Limited – Director
Chairman/Member in the Committees of the Boards of this and other listed companies in which he is a director	1. Stakeholders' Relationship Committee - Member
Relationship between Directors / Manager and other KMPS	NA

ITEM NO. 3.

Mr. H.A. Parikh (DIN: 00027820) who was appointed as an Additional Director by the Board of Directors of the Company ("the Board") based on the recommendation of the Nomination and Remuneration Committee under the category of Non-Executive Non-Independent Director with effect from June 18th, 2026, pursuant to the provisions of Section 152, 161(1) and all other applicable provisions of the Companies Act, 2013 read with the Companies (Appointment and Qualifications of Directors) Rules, 2014 (including any statutory modification(s) or enactment thereof for the time being in force) (the "Act"), the provisions of the Articles of Association of the Company who holds office up to the date of the next Annual General Meeting of the Company.

The Board of Directors, on the recommendation of the Nomination and Remuneration Committee, is of the view that the appointment of Mr. H.A Parikh on the Company Board is desirable and would be beneficial to the Company and hence it recommends the said resolution No.3 for approval by the members of the Company.

Further, Mr. H.A Parikh has confirmed that he is not disqualified to act as a Director in terms of Section 164 of the Act and he is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority and he is in compliance with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014. Given his expertise, knowledge and experience, the Board is of the opinion that it would be in the interest of the Company to avail his services as a non-executive non-independent director of the Company.

ANNEXURE TO ITEM NO. 3 OF THE NOTICE

Name of the Director	H. A. Parikh
Date of Birth	07/08/1964
Nationality	Indian
Date of Initial Appointment	18.06.2026
Qualifications	BACHELOR IN CHEMICAL ENGINEERING
Experience and Expertise in specific functional area	Mr. Parikh H. A. is a Promoter of the Company. He holds a Bachelor Degree in Chemical Engineering having more than 30 years of experience as a leading business entrepreneur in various sectors, specialized in setting up diverse Pharmaceutical and Biotechnology projects. His entrepreneurial spirit will contribute to the overall growth and success of the Company.
Terms and Conditions of appointment	As per Resolution
No. of Board Meeting attended during the year	5 (Five)
Number of shares held in the Company	100,000
Designation	Non-executive Director
Other directorships held including in listed entity	1. Viva Energy Fertilizers Private Limited- Director 2. Vivanta Industries Limited- Managing Director 3. Vitaaglobal Bioscience Private Limited- Director 4. Vital I.P. Private Limited- Director 5. Vitale Beverages Private Limited-Director
Chairman/Member in the Committees of the Boards of this and other listed companies in which he is a director	NA
Relationship between Directors / Manager and other KMPS	NA

ITEM NO. 4.

Pursuant to the provisions of Section 188 of the Companies Act, 2013 read with the Companies (Meeting of Board and its Powers) Rules, 2014, the Related Party Transactions as mentioned in clause (a) to (g) of the said section require a Company to obtain approval of the Board of Directors and subsequently the Shareholders of the Company by way of ordinary resolution in case the value of the Related Party Transactions exceeds the stipulated thresholds prescribed in Rule 15 of the said Rules and transactions other than in ordinary course of business and on arm’s length basis.

Further, Regulation 23(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015, (“Listing Regulations”) also stipulates that all material related party transactions shall require prior approval of the shareholders through ordinary resolution.

Further, SEBI vide its Circular no. SEBI/HO/CFD/CMD1/CIR/P/2022/47 dated 8th April, 2022 clarified that the shareholders’ approval of omnibus RPTs approved in an Annual General Meeting shall be valid up to the date of the next Annual General Meeting for a period not exceeding fifteen months.

During the financial year 2026-2027, the Company and few related entities, propose to enter into certain related party transaction(s) as mentioned in the Enclosure to the Notice, on mutually agreed terms and conditions, and the aggregate of such transaction(s) is up to Rs.100 Crore (One Hundred Crore Only), as per the SEBI Listing Regulations, prior approval of the Members is being sought for all such arrangements / transactions proposed to be undertaken by the Company, either directly or along with its subsidiary(ies). All the said transactions shall be in the ordinary course of business of the Company and on an arm’s length basis. The Audit Committee has, on the basis of relevant details provided by the management as required by the law, reviewed and approved the said transaction(s), subject to approval of the Members, while

noting that such transaction shall be on arms length basis and in the ordinary course of business and are in accordance with the Related Party Policy of the Company.
The Board of Directors recommend the said resolutions, asset out in item no. 4 of this Notice, for your approval. The Members may note that in terms of the provisions of the SEBI Listing Regulations, the related parties as defined thereunder (whether such related party(ies) is a party to the aforesaid transactions or not), shall not vote to approve the said resolutions. Promoters of the Company and their relatives are deemed to be concerned or interested in these resolutions.

Enclosure-A

Sr. No.	Name of the entity
1.	VIPRONOVA LIFESCIENCE PRIVATE LIMITED
2.	ADLINE CHEM LAB LIMITED
3.	VITAAGLOBAL BIOSCIENCE PRIVATE LIMITED
4.	MEGHDHANUSH DRONES & AGRO TECHNOLOGIES PRIVATE LIMITED
5.	TRINITY GANESH PRIVATE LIMITED
6.	VITALEDGE NEXTGEN ADVISORY CONSULTING PRIVATE LIMITED
7	VIVA ENERGY FERTILIZERS PRIVATE LIMITED
8	VITAL INTERIORS & FURNITURES PRIVATE LIMITED
9	VAISHALI LIFECARE PRIVATE LIMITED
10	VIRTUAL TO VISUAL JEWELLERY DESIGNS PRIVATE LIMITED
11	VIVANTA INDUSTRIES LIMITED
12	VIVANZA LIFESCIENCES PRIVATE LIMITED
13	VITALE BEVERAGES PRIVATE LIMITED
14	V-CREATE PAPER SOLUTION PRIVATE LIMITED
15	VINTRON INFRASTRUCTURE AND PROJECTS PRIVATE LIMITED
16	VIVANTA INDUSTRIES LIMITED
17	CKIM PHARMA LLP
18	VIVA SURBHI BIOTECH LLP
19	MAA TRADELINK LLP
20	MAHA SHREE REALTY LLP
21	MOUSER VENTURE LLP
22	JAYENDRA MEHTA- MANAGING DIRECTOR
23	SARANG PATHAK - NON EXECUTIVENON INDEPENDENT DIRECTOR
24	H.A. PARIKH - NON EXECUTIVE INDEPENDENT DIRECTOR
25	REENA KUMARI- INDEPENDENT DIRECTOR
26	HITESH RIJWANI- INDEPENDENT DIRECTOR
27	PARTH A. PARIKH – PROMOTER OF THE COMPANY

None of the other Directors, Key Managerial Personnel of the Company and their relatives, is in any way, concerned or interested, financially or otherwise, in the proposed resolutions, as set out in Item nos. 4 of this Notice.

ITEM NO. 5 & 6.
The existing Memorandum of Association ("MOA") and Articles of Association ("AOA") of the Company were originally adopted under the provisions of the Companies Act, 1956.
Over the years, the Companies Act, 2013, together with the Rules framed thereunder, has replaced the Companies Act, 1956. In addition, the regulatory framework applicable to listed companies has undergone significant changes with the introduction and subsequent amendments to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and various other corporate governance requirements.

Accordingly, the existing MOA and AOA contain several references to the provisions of the Companies Act, 1956, certain provisions which are no longer applicable and various clauses that require updating to align them with the provisions of the Companies Act, 2013 and the applicable regulatory framework.

The proposed substitution of the Memorandum of Association is being carried out pursuant to Section 13 of the Companies Act, 2013 and requires approval of the Members by way of a Special Resolution.

The proposed substitution of the Articles of Association is being carried out pursuant to Section 14 of the Companies Act, 2013 and also requires approval of the Members by way of a Special Resolution.

Copies of the existing Memorandum of Association and Articles of Association, together with the proposed new Memorandum of Association and Articles of Association indicating the changes, are available for inspection by the Members during business hours on all working days up to the date of the Annual General Meeting. The same shall also be available for electronic inspection by the Members in accordance with the applicable provisions of the Companies Act, 2013.

The Board of Directors recommends the Special Resolutions set out at Item Nos. 5 and 6 of the Notice for approval of the Members.

None of the Directors, Key Managerial Personnel of the Company or their respective relatives is, in any way, concerned or interested, financially or otherwise, in the proposed resolutions except to the extent of their shareholding, if any, in the Company.

ITEM NO. 7

Section 180(1)(c) of the Companies Act, 2013 ("the Act"), requires that the Board shall only exercise the powers to borrow money, where the money to be borrowed, together with the money already borrowed by the Company exceeds aggregate of its paid-up share capital, free reserves and securities premium, apart from temporary loans obtained from the Company's bankers in the ordinary course of business, only with the consent of the Members by passing a special resolution.

In view of the aforesaid Proposed Transactions and given the Company's existing and future financial requirements, the Company shall require additional funds and for this purpose, the Company is desirous of raising finance from banks/ financial institutions/investors or any other lender or through issuance of convertible/non-convertible debentures or any other persons as may be considered fit, which, together with the moneys already borrowed by the Company and the monies to be borrowed (apart from temporary loans obtained from the Company's bankers in ordinary course of business) may exceed the aggregate of the paid-up capital, free reserves and securities premium of the Company, which sum not exceeding INR 100 crores (Rupees One HundredCrores only), on such terms and conditions as it may deem fit under Section 180(1)(c) of the Act.

It is, therefore, proposed to seek the approval of the Members to increase the borrowing limits to INR 100 crores (Rupees One Hundredcrores only), by way of a special resolution.

The above proposal is in the interest of the Company and the Board recommends the Special Resolution as set forth in Item No. 7 of the Notice for approval by the Members of the Company.

None of the Directors or Key Managerial Personnel or their relatives are in any way concerned with orinterested, financially or otherwise in the said resolution except to the extent of their shareholding in the Company, if any.

ITEM NO. 8

In terms of the provisions of Section 186 of the Companies Act, 2013 and rules made thereunder, no Company shall directly or indirectly, without prior approval by means of a special resolution passed at a general meeting, give any loan to any person or other body corporate or give guarantee or provide security in connection with a loan to any other body corporate or person and acquire by way of subscription, purchase or otherwise the securities of any other body corporate, exceeding 60% of its paid up share capital, free reserves and securities premium account or 100% of its free reserves and securities premium account, whichever is more.

In view of the Proposed Transactions, the Company may be required to make investment or to give loan or to extend guarantee/letter of comfort/letter of support/security in connection with loan taken by affiliate/joint venture/associate/subsidiary of the Company or any other body corporate. Hence, consent of the Members is being sought by way of a special resolution to make investment or to give loan/guarantee or provide security/letter of comfort/letter of support to other body corporate upto INR 50 (Fifty Crores Only), in excess of limits specified under Section 186 of the Companies Act, 2013, as set out at Item No. 8 of this Notice.

ITEM NO. 9

In view of the aforesaid Proposed Transactions, the Company may have to render support for the business requirements of its subsidiary companies or associate or joint venture or group entity or any other person in whom any of the Director of the Company is deemed to be interested (collectively referred to as the “Entities”), from time to time. Hence, the Board seeks consent of the Members by way of a Special Resolution pursuant to Section 185 of the Act for making loan(s) or providing financial assistance or providing guarantee or securities or letter of support or letter of comfort in connection with the loans taken or to be taken by the Entities as may be required by the Entities from time to time for the expansion of its business activities and other matters connected and incidental thereon for their principal business activities. The Members may note that the Board of Directors thereof would carefully evaluate proposals and provide such loan, guarantee or security through deployment of funds out of internal resources/accruals and/or any other appropriate sources, from time to time, only for principal business activities of such Entities.

The above proposal is in the interest of the Company and the Board recommends this Special Resolution as set forth in Item No. 9 of the Notice for approval by the Members of the Company.

Save and except as provided above, none of the Directors or Key Managerial Personnel or their relatives are in any way concerned with or interested, financially or otherwise in the said Resolution except to the extent of their shareholding in the Company, if any.

Director's Report

To,
The Members,
Vivanza Biosciences Limited

Your directors are pleased to present the 44th (Forty-Fourth) Annual Report of your company together with the Audited Financial Statement of your company for the financial year ended 31st March, 2026.

1. FINANCIAL SUMMARY/HIGHLIGHTS OF PERFORMANCE OF THE COMPANY:

				(Rs.in Lacs)
	Standalone		**Consolidated**	
Particulars	**Year ended 31/03/2026**	**Year ended 31/03/2025**	**Year ended 31/03/2026**	**Year ended 31/03/2025**
I. Total Revenue	11,234.04	297.74	11,602.21	748.48
II. Total Expenditure	11,182.25	367.10	11,547.84	815.05
III. Profit/(Loss) Before Tax (I-II)	51.79	(69.36)	54.37	(66.57)
IV. Provision for Taxation	14.29	0.15	14.93	0.84
V. Profit/(Loss) After Tax (III-IV)	37.50	(69.51)	39.44	(67.41)

2. PERFORMANCE AND STATE OF AFFAIRS OF THE COMPANY:
During the year under review, the Company has earned revenue of Rs. 11,234.04 lacs. The Board of Directors of the Company is continually working to drive the Company's growth.

3. CHANGE IN NATURE OF BUSINESS:
During the financial year, there have not been any changes in the nature of business of the Company.

4. DIVIDEND:
The Board of Directors has not recommended any dividend during the year under review. In terms of Regulation 43A of the Listing Regulations, the Board of Directors of the Company has adopted a Dividend Distribution Policy, which sets out the parameters and circumstances to be considered by the Board in determining the distribution of dividend to its shareholders. These parameters include Company's distributable profits, utilization and future plans, capital expenditure and such other factors as may be considered by the Board for optimum dividend pay-outs. The Dividend Distribution Policy is available on the Company's website atwww.vivanzabiosciences.com

5. TRANSFER TO RESERVE:
Reserves & Surplus at the end of the year stood at Rs. 39,54,000 as compared to Rs. 2,04,000 at the beginning of the year.

6. SHARE CAPITAL:
At present, the Company has only one class of shares – equity shares with face value of Rs.1/- each. AUTHORIZED SHARE CAPITALThe Authorized Share Capital of the Company is Rs.4,00,00,000/- divided into 4,00,00,000 equity shares of Rs.1/- each.

ISSUED, SUBSCRIBED AND PAID-UP SHARE CAPITAL:
The issued, subscribed paid up share capital of the company as on March 31, 2026 is Rs. 4,00,00,000/- divided into 4,00,00,000 equity shares of Rs.1/- each.

7. **MATERIAL CHANGES AND COMMITMENTS IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT**

No Material changes have occurred during the year which shall affect the Financial position of the Company.

8. **PERFORMANCE AND FINANCIAL POSITION OF EACH OF THE SUBSIDIARIES, ASSOCIATES, AND JOINT VENTURE COMPANIES**

No Company has become or ceased to be subsidiary/Joint venture/Associate Company of the Company during the year. However, the Company has one wholly owned subsidiary Company i.e.

Sr. No	Name of Subsidiary	Status
1.	Vivanza Lifesciences Private Limited	Wholly Owned Subsidiary

Form AOC-1 in this regard is attached at the end of the financial statements as Annexure-A.

9. **DEPOSITS**

The Company has neither accepted nor renewed any deposit within the meaning of the Companies (Acceptance of Deposits) Rules, 2014.

10. **DISCLOSURE REGARDING ISSUE OF EMPLOYEE STOCK OPTION:**

Company has not issued any Employee Stock Option during the year.

11. **ANNUAL RETURN ON WEBSITE**

Draft of Annual Return as on 31st March, 2026 in Form MGT-7 is available on the website of the Company www.vivanzabiosciences.com.

12. **DISCLOSURE REGARDING ISSUE OF SWEAT EQUITY SHARES**

During the year, the Company has not issued Sweat Equity shares. Hence, details as per Rule 8(13) of the Companies (Share Capital and Debentures) Rule, 2014 are not reported yet.

13. **CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO**

The Company continues to accord high priority to the conservation of energy and natural resources as part of its operational and sustainability objectives.

The Company continued its efforts towards technology absorption through the adoption of advanced manufacturing technologies, automation and process improvement initiatives aimed at enhancing manufacturing efficiency, product quality and productivity.

The details foreign exchange earnings and outgo are as under.

Particulars	2025-26	2024-25
Foreign Exchange Earning	668.36	120.96
Foreign Exchange Outgo	---	---

14. **CORPORATE SOCIAL RESPONSIBILITY (CSR)**

Corporate Social Responsibility (CSR) is not applicable to the Company during the year.

15. **DIRECTORS AND KEY MANAGERIAL PERSONNEL**

A. **Details of Appointment/resignation of Directors and Key Managerial Personnel**

Mr Sarang Bharatbhai Pathak (DIN: 02663344) was appointed as an Additional Director at a Board Meeting held on 30th August, 2025, as a Non-Executive Non-Independent Director, and upon receipt of shareholders’ approval the appointment was approved at the Annual General Meeting held on 25th September, 2025.

Mr. Hitesh Rijwani (DIN:11030634) was appointed as an Additional Director at a Board Meeting held on 12th May, 2025 as a Non-Executive Independent Director for the period of five years and upon receipt of shareholders’ approval the appointment was approved by Member at Annual General Meeting held on 25th September,2025.

Mr. H A Parikh has resigned from the position of Non- Executive Director w.e.f. 17th March, 2026.

Mr. Aagam Shah has resigned from the position of Non- Executive Independent Director w.e.f. 11th May, 2025.

Ms. Siddhi Shah has Resigned from the post of Company Secretary and Compliance Officer w.e.f 26th September, 2025.

Mr. Chaitra Arora has been appointed as a Company Secretary and Compliance Officer w.e.f. 11th November, 2025.

EVENTS OCCURRING AFTER THE CLOSER OF THE FINANCIAL YEAR
Mr. H. A. Parikh has been appointed as a Non- Executive Non-independent Additional Director w.e.f. 18thJune, 2026.

Mr. Chaitra Arora has Resign from the post of Company Secretary and Compliance Officer w.e.f. 30th April, 2026.

Mr. Vishal Katarmal has been appointed as aCompany Secretary and Compliance Officer w.e.f. 09th July, 2026.

RETIRE BY ROTATION:
Pursuant to the provisions of Section 152 of the Companies Act, 2013 read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and the Articles of Association of your Company, Mr. Jayendra Mehta (DIN: 08210602), Managing Director of the Company, is liable to retire by rotation at the ensuing AGM and, being eligible, has offered themselves for reappointment
Appropriate resolutions for their re-appointment are being placed for your approval at the ensuing AGM.
Your Directors recommend their re-appointment as the Managing Director and Executive Director, respectively of your Company.

B. STATEMENT ON DECLARATION GIVEN BY INDEPENDENT DIRECTORS UNDER SECTION 149(6) OF THE ACT

The Board of Directors hereby declares that all the independent directors duly appointed by the Company have given the declaration and they meet the criteria of independence as provided under Section 149(6) of the Act.

C. STATEMENT WITH REGARDS TO INTEGRITY, EXPERTISE AND EXPERIENCE OF INDEPENDENT DIRECTORS

Your Directors are of the opinion that the Independent Directors of the Company are of high integrity and suitable expertise as well as experience (including proficiency)

D. FORMAL ANNUAL EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17 and Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a structured questionnaire was prepared after taking into consideration of the various aspects of the Board's functioning, Composition of the Board and Committees, culture, execution and performance of specific duties, obligation and governance. The performance evaluation of the Independent Directors was completed.

During the financial year under review, the Independent Directors met on 12th May, 2025 inter alia, to discuss:

• Performance evaluation of Non-Independent Directors and Board of Directors as a whole;

• Performance evaluation of the Chairman of the Company;

• Evaluation of the quality of flow of information between the Management and Board for effective performance by the Board.

The Board of Directors expressed their satisfaction with the evaluation process.

E. POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION

The Company has a Nomination and Remuneration Committee. The Committee reviews and recommends to the Board of Directors about remuneration for Directors and Key Managerial Personnel and other employees up to one level below Key Managerial Personnel. The Company does not pay any remuneration to the Non-Executive Directors of the Company other than a sitting fee for attending the Meetings of the Board of Directors and Committees of the Board. Remuneration to Executive Directors is governed by the relevant provisions of the Act and approvals.

The Company has devised the Nomination and Remuneration Policy for the appointment, re-appointment and remuneration of Directors, Key Managerial Personnel and Senior Management Personnel. All the appointment, re-appointment and remuneration of Directors, Key Managerial Personnel and Senior Management Personnel are as per the Nomination and Remuneration Policy of the company.

16. MEETINGS

A calendar of Meetings is prepared and circulated in advance to the Directors. During this year, Six Board meetings were held, which are as follows. 12.05.2025, 13.08.2025, 30.08.2025, 01.09.2025, 11.11.2025, 12.02.2026.

The intervening gap between the Meetings was within the period prescribed under The Act and The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015[LODR].

POSTAL BALLOT:

During the Financial Year 2025-26, the following special resolutions were passed by the Company through postal ballot notice dated November 11, 2025 and approved by the shareholders on December 06, 2025:

Sr. No.	Special Resolution	No of votes polled	No. and % of votes in favour	No. and % of votes against
1.	Alteration of the object clause of the memorandum of association of the company	51,11,539	51,06,561 (99.90%)	4,978 (0.10%)

The following actions were conducted pursuant to the approval of the Board and in compliance with the provisions of the Act and MCA Circulars:

i. Mr. Chintan K. Patel (Membership No: A31987), Proprietor of Chintan K. Patel, Practising Company Secretary (COP No. 11959), was appointed as the Scrutinizer for conducting the Postal Ballot only through Remote E-voting in a fair and transparent manner;

ii. The Company availed the services of M/s. Purva Sharegistry (India) Private Limited for providing the Remote E-voting facility to the Members;

iii. A newspaper advertisement as required under the Act and the MCA Circulars was published on November 15, 2025, in the English and Gujarati editions of Indian Express and Financial Express, respectively;

iv. The Remote E-voting period commenced at 9:00 a.m. (IST) on Monday, November 17th, 2025 and ended at 5:00 p.m. (IST) on Tuesday, December 16th, 2025

17. DETAILS OF ESTABLISHMENT OF VIGIL MECHANISM FOR DIRECTORS AND EMPLOYEES

The Company has established a vigil mechanism and accordingly framed a Whistle Blower Policy. The policy enables the employees to report to the management instances of unethical behaviour, actual or suspected fraud or violation of Company's Code of Conduct.

Further the mechanism adopted by the Company encourages the Whistle Blower to report genuine concerns or grievances and provide for adequate safe guards against victimization of Whistle Blower who avails of such mechanism and also provides for direct access to the Chairman of the Audit Committee, in exceptional cases.

The functioning of vigil mechanism is reviewed by the Audit Committee from time to time. None of the Whistle blowers has been denied access to the Audit Committee of the Board. The Whistle Blower Policy of the Company is available on the website of the Company www.vivanzabiosciences.com.

18. PARTICULARS OF LOANS GIVEN, GUARANTEES GIVEN, INVESTMENTS MADE AND SECURITIES PROVIDED

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the Notes to the Financial Statements.

19. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

Particulars of contracts or arrangements with related parties in Form AOC-2 are enclosed as per Annexure-B.

20. MANAGERIAL REMUNERATION

Disclosures pursuant to Section 197(12) of The Companies Act, 2013 read with Rule 5(1), 5(2) and 5(3) of The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are enclosed herewith as per Annexure-D.

21. AUDITORS

• INTERNAL AUDITOR

Section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014 and based on the recommendations made by the Audit Committee M/s. Dharti Shah & Co Chartered Accountants, Ahmedabad has been appointed as the Internal Auditors for carrying out the Internal Audit of the company for the FY 2026-2027.

• STATUTORY AUDITORS

M/s. Shivam Soni & Co., Chartered Accountant have been appointed as Statutory Auditors of the Company from the conclusion of the 40th Annual General Meeting to hold office upto the conclusion of 46th Annual General Meeting.

• SECRETARIAL AUDITORS

M/s. Chintan Patel & Associates, Practicing Company Secretaries, Ahmedabad, Gujarat, were appointed as Secretarial Auditors, to carry out Secretarial Audit of the Company as per provisions of Section 204 of The Companies Act, 2013 and issue of Annual Secretarial Compliance certificate pursuant to Regulation 24A of LODR. The Secretarial Audit Report have been annexed to this Report as per Annual Annexure E

• Explanation or Comments on disqualifications, reservations, adverse remarks or disclaimers in the Auditor's Reports;

STATUTORY AUDITOR'S REPORT AND SECRETARIAL AUDIT REPORT

Neither the Statutory Auditors nor the Secretarial Auditors of the Company in their respective draft reports, have made any qualifications, reservations, adverse remarks or disclaimers. Accordingly, no explanations/ comments thereon are required to be furnished.

22. CORPORATE GOVERNANCE REPORT

As per Regulation 15(2) of the SEBI Listing Regulations, compliance with the corporate governance provisions as specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 and para C, D and E of Schedule V, shall not apply in respect of the listed entity having paid up equity share capital not exceeding rupees ten crore and net worth not exceeding rupees twenty five crore, as on the last day of the previous financial year. At present, the Company is not required to comply with Corporate Governance regulations as none of the above referred limits have been triggered.

23. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

A report on Management Discussion and Analysis, as required in terms of Regulation 34(2) of LODR forms part of this Report. It deals with the Business Operations and Financial Performance, Research & Development Expansion & Diversification, Risk Management, Marketing Strategy, Safety & Environment, Human Resource Development, etc. enclosed as per Annexure-H

24. RISK MANAGEMENT

The Company is aware of the risks associated with the business. It regularly analyses and takes corrective actions for managing/mitigating the same.

The Company has framed a formal Risk Management Framework for risk assessment and risk minimization which is periodically reviewed to ensure smooth operation and effective management control. The Audit Committee also reviews the adequacy of the risk management framework of the Company, the key risks associated with the business and measure and steps in place to minimize the same.

25. DIRECTORS' RESPONSIBILITY STATEMENT

As stipulated in Section 134(3)(c) read with sub section 5 of the Companies Act, 2013, Directors subscribe to the "Directors' Responsibility Statement", and confirm that:

a) In preparation of annual accounts for the year ended 31st March, 2026, the applicable accounting standards have been followed and that no material departures have been made from the same;

b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that year;

c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) The Directors had prepared the annual accounts for the year ended 31stMarch, 2026 on going concern basis.

e) The Directors had laid down the internal financial controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively; and

f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

26. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Your Company is committed to providing a safe, respectful and equal-opportunity workplace and follows a zero-tolerance policy towards sexual harassment. In line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 ("POSH Act") and the rules made thereunder, the Company has adopted a comprehensive POSH Policy covering all employees, including permanent, temporary, contractual, and trainees. The policy clearly sets out procedures for prevention, prohibition, and redressal of complaints, along with guidelines for investigation and resolution.

In accordance with the provisions of the POSH Act, the Company has duly constituted Internal Complaints Committees (ICCs), including an external member, at the Corporate Office as well as at plant. The ICC is entrusted with the responsibility of addressing and resolving complaints in a fair, impartial, and timely manner. Your Company also conducts regular awareness and sensitization programmes, including employee induction sessions, to promote understanding of the POSH framework and encourage a respectful work culture.

Details of Sexual Harassment Complaints received during the year under review are as follows:

Particulars	Number of Complaints
No. of Complaints of Sexual Harassment received in the year	NIL
No. of Complaints disposed off during the year	NIL
No. of cases pending for more than ninety days	NIL

27. DIRECTORS TRAINING & FAMILIARIZATION

The Directors are regularly informed during the meetings of the Board and the Committees, of the activities of the Company, its operations and issues faced by the Engineering Industry. Considering the long association of the Directors with the Company and their seniority and expertise in their respective areas of specialization and knowledge of the engineering industry, their training and familiarization were conducted in the below mentioned areas:

- The Roles, Rights, Responsibilities and Duties of Independent Directors
- Business Development Strategy and Plans
- Changes brought in by the introduction of the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
- Changes in the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

28. AUDIT COMMITTEE

The Audit Committee of the Board consists of Two Independent and One Executive Non-Independent Director. The composition, role, terms of reference as well as power of the Audit Committee are in accordance with the provisions of Regulation 18 of LODR and Section 177 of The Act and Rules framed thereunder.

The details of all related party transactions are placed periodically before the Audit Committee. All the recommendations made by the Audit Committee were accepted by the Board. The Company has in place a Vigil Mechanism; details of which are available on the Company's website.

The Audit Committee comprises of the following Members as on March 31, 2026-

Name	Designation	Category
Ms. Rina Kumari	Chairman	Non-Executive, Independent Director
Mr. Hitesh Rijwani	Member	Non-Executive, Independent Director
Mr. Jayendra Mehta	Member	Executive Director

*Mr. Hitesh Rijwani has been appointed as Non-ExecutiveIndependent Directorw.e.f 12.05.2025

There were 4 (Four) Meetings of the Audit Committee of the Board of Directors held during the Financial Year 2025-26, (i.e. 12th May, 2025, 13th August, 2025, 11th November, 2025, 12th February, 2026).

The Statutory Auditors and Chief Financial Officer attend the Audit Committee Meetings as Invitees. The Company Secretary and Compliance Officer acts as Secretary to the Audit Committee. The Audit Committee has made observations and recommendations to the Board of Directors, which have been noted and accepted by the Board.

During the Financial Year 2025-26, all recommendations made by the Audit Committee to the Board of Directors were accepted by the Board and there were no instances where the recommendations were not accepted.

29. NOMINATION AND REMUNERATION COMMITTEE

In compliance with Section 178 of The Act, Your Company has in place a "Nomination and Remuneration Committee". The powers, role and terms of reference of the Nomination and Remuneration Committee cover the areas as contemplated under Regulation 19 of LODR and Section 178 of The Act, and Rules and Regulations, framed thereunder, besides other terms as may be referred by the Board of Directors.

The Nomination and Remuneration Committee comprises of the following Members as on March 31st, 2026:-

Name	Designation	Category
Ms. Rina Kumari	Chairman	Non-Executive, Independent Director
Mr. Hitesh Rijwani	Member	Non-Executive, Independent Director
Mr. Jayendra Mehta	Member	Executive Director

*Mr. Hitesh Rijwani has been appointed as Non-Executive, Independent Director w.e.f 12.05.2025
There was 3 (Three) Meetings of the Nomination and Remuneration Committee of the Board of Directors held during the Financial Year 2025-26 (i.e., on 12th May 2025, 30th August,2025, 11th November, 2025).

30. STAKEHOLDERS' RELATIONSHIP COMMITTEE:

Pursuant to the provisions of Section 178 of the Companies Act, 2013, your Company has constituted a Stakeholders' Relationship Committee of the Board of Directors, comprising of the following Members during the Financial Year 2025-26:-

Name	Designation	Category
Ms. Rina Kumari	Chairman	Non-Executive, Independent Director
Mr. Hitesh Rijwani	Member	Non-Executive, Independent Director
Mr. Jayendra Mehta	Member	Executive Director

*Mr. Hitesh Rijwani has been appointed as Non-Executive, Independent Director w.e.f 12.05.2025

During the Financial Year 2025-2026, 4 (Four) Meeting of the Stakeholders' Relationship Committee was held, (i.e., on 15.05.2025, 11.08.2025, 20.11.2025 and 10.01.2026)

31. SECRETARIAL STANDARDS

During the year under Report, the Company has complied with the applicable provisions of Secretarial Standards as issued and notified by The Institute of Company Secretaries of India and approved by the Central Government.

32. INTERNAL CONTROL SYSTEM

Your company maintains a robust system of internal controls designed to safeguard all assets from unauthorized use or misappropriation. Every transaction undergoes stringent processes to ensure proper authorization, accurate recording, and precise reporting. Our internal controls are fortified by a comprehensive program of both internal and external audits, complemented by regular management reviews. These audits ensure the accuracy of financial and operational records, supporting reliable financial reporting and reinforcing accountability for asset stewardship.

The Audit Committee plays a pivotal role in governance, overseeing the effectiveness of our internal controls and compliance initiatives. It reviews audit performance and ensures alignment with regulatory standards.

In the sincere judgment of the Board of Directors and our senior management, our internal control framework is sound, functioning efficiently, and fully capable of supporting the company's operational and reporting objectives.

33. SHAREHOLDERS' DISPUTE RESOLUTION MECHANISM:

SEBI vide circular July 31, 2023 and subsequent circular dated December 20, 2023, read with Master Circular dated August 11, 2023, has specified that a shareholder shall first take up his/her/their grievance with the listed entity/RTA by lodging a complaint directly with the concerned listed entity/RTA and if the grievance is not redressed satisfactorily, the shareholder may, in accordance with the SCORES guidelines, escalate the same through the SCORES Portal in accordance with the process laid out therein. Only after exhausting all available options for resolution of the grievance, if the shareholder is not satisfied with the outcome, he/she/ they can initiate dispute resolution through the Online Dispute Resolution ("ODR") Portal. Shareholders are requested to take note of the same.

34. SUSPENSION OF TRADING

The equity shares of the Company have been listed and actively traded on the Main Board of Bombay Stock Exchange (BSE) Limited. There was no occasion on which the equity shares of the Company have been suspended for trading during the FY 2025-2026.

35. REPORTING OF FRAUDS

During the year under review, none of the Auditors have reported any instances of fraud committed in the Company by its officers or employees to the Audit Committee, as required under Section 143 (12) of the Act.

36. MATERNITY BENEFITS

Your Company complies with the provisions of the Maternity Benefit Act, 1961, and provides Maternity Benefits to eligible women employees. Adequate facilities and support are provided in line with statutory requirements.

37. LISTING FEES:

The Company affirms that the annual listing fees for the year 2025-2026 to The Bombay Stock Exchange Limited have been duly paid.

38. AUDIT TRAIL APPLICABILITY (AUDIT AND AUDITORS) RULES, 2014 – RULE 11 OF THE COMPANIES ACT, 2013

The Company had used accounting software for maintaining its books of account for the financial year ended March 31st, 2026, which has a feature of recording audit trail (edit log) facility, and the same has operated throughout the year for all relevant transactions recorded in the software.

39. NO APPLICATION/ PROCEEDING UNDER IBC

Neither any application is made, nor any proceeding is pending under the Insolvency and Bankruptcy Code, 2016 (IBC) during the year under review, and accordingly the Company has no information to offer in this regard

40. WEBSITE DISCLOSURES:

In compliance with the applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company maintains a functional website www.vivanzabiosciences.comcontaining details of its business activities, financial information, statutory disclosures, policies, codes, notices, annual reports and other investor-related information

41. CAUTIONARY STATEMENT:

Statements in the Board's Report and the Management Discussion & Analysis describing the Company's objectives, expectations or forecasts may be forward-looking within the meaning of applicable securities laws and regulations. Actual results may differ materially from those expressed in the statement. Important factors that could influence the Company's operations include global and domestic demand and supply conditions affecting selling prices of finished goods, input availability and prices, changes in government regulations, tax laws, economic developments within the country and other factors such as litigation and industrial relations.

42. ACKNOWLEDGEMENTS

Your Directors wish to place on record sincere appreciation for the support and co-operation received from various Central and State Government Departments, organizations and agencies. Your Directors also gratefully acknowledge all stakeholders of your Company, viz., Shareholders, customers, dealers, vendors, banks and other business partners for excellent support received from them during the Financial Year under review. Your Directors also express their warm appreciation to all the employees of the Company for their unstinted commitment and continued contribution to the growth of your Company.

Place: Ahmedabad
Date: August 17, 2026

For and on behalf of the Board
For, Vivanza Biosciences Limited

Sd/-	Sd/-
Jayendra Mehta	**Sarang Pathak**
Managing Director	Director
DIN:08210602	DIN:02663344

ANNEXURE-A TO THE DIRECTORS' REPORT
FORM NO. AOC-1

Part “A”: Subsidiaries

1	Name of the subsidiary	Vivanza Lifesciences Private Limited
2	The date since when subsidiary was acquired	17/06/2016
3	Reporting period for the subsidiary	2025-2026
4	Reporting currency and Exchange rate as on the last date of the relevant Financial year	INR (Rs. in lacs)
5	Share capital	100.00 (Rs. in lacs)
6	Reserves & surplus	-73.02
7	Total assets	416.84
8	Total Liabilities	389.86
9	Investments	0.00
10	Revenue from Operations	367.95
11	Profit/(loss) before taxation	2.58
12	Provision for taxation	0.64
13	Profit/(loss) after taxation	1.94
14	Proposed Dividend	Nil
15	% of shareholding	100% held by Vivanza Biosciences Limited

2. Names of subsidiaries which are yet to commence operations - None
3. Names of subsidiaries which have been liquidated or sold during the year. - NA

Part “B”: Associates and Joint Ventures
There are no Associates of the Company.

Place: Ahmedabad
Date: August 17, 2026

For and on behalf of the Board
For, Vivanza Biosciences Limited

Sd/-
Jayendra Mehta
Managing Director
DIN:08210602

Sd/-
Sarang Pathak
Director
DIN:02663344

ANNEXURE – B TO THE DIRECTORS REPORT

FORM NO. AOC-2

(Pursuant to clause (h) of sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto:

1. Details of contracts or arrangements or transactions not at arm's length basis: NIL

Sr. No.	Particulars	Remarks
1	Name(s) of the related party and nature of relationship	NIL
2	Nature of contracts/arrangements/transactions	
3	Duration of the contracts / arrangements/transactions	
4	Salient terms of the contracts or arrangements or transactions including the value, if any	
5	Justification for entering into such contracts or arrangements or transactions	
6	Date(s) of approval by the Board	
7	Amount paid as advances, if any	
8	Date on which the special resolution was passed in general meeting as required under first proviso to Section 188	

2. Details of material contracts or arrangements or transactions at arm's length basis:

The details of contracts or arrangements or transactions at arm's length basis for the financial year ended March 31, 2026, are detailed in the Notes to Financial Statement annexed to the Annual Report for which appropriate approvals have been taken as applicable from time to time.

Apart from this, there were no material contracts or arrangements or transactions entered into during the year ended March 31, 2026.

Place: Ahmedabad
Date: August 17, 2026

For and on behalf of the Board
For, Vivanza Biosciences Limited

Sd/-
Jayendra Mehta
Managing Director
DIN:08210602

Sd/-
Sarang Pathak
Director
DIN:02663344

ANNEXURE-C TO THE DIRECTORS REPORT
Disclosure under Para A of Schedule V of the Listing Regulation

(Rs.in Lacs)

Sr. No.	Disclosure of loan/advances/investments/outstanding during the year	As at 31st March, 2026.	Maximum amount during the year
1	Loans and advances in the nature of loans to subsidiary	18.07	1.03
2	Loans and advances in the nature of loans to associate	--	--
3	Loans and advances in the nature of loans to firm/company in which directors are interested	6.38	--

Place: Ahmedabad
Date: August 17, 2026

For and on behalf of the Board
For, Vivanza Biosciences Limited

Sd/-
Jayendra Mehta
Managing Director
DIN:08210602

Sd/-
Sarang Pathak
Director
DIN:02663344

ANNEXURE-D TO THE DIRECTORS REPORT
MANAGERIAL REMUNERATION

Details pertaining to remuneration as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the Financial Year 2025-26 and the ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial Year 2025-2026 is as under:

(Rs.in Lacs)

Sr. No.	Name of Director/KMP and its Designation	Designation of Director/KMP	During the the Financial Year 2025-26 no increase in the Remuneration.	Ratio of Remuneration of each Director to the Median Remuneration of Employees
1	Mr. Jayendra Mehta	Chairman &Managing Director	--	--
2.	*Mr. H. A. Parikh	Non-Executive Director	--	--
3.	Mr. Sarang B. Pathak	Non-Executive Director	--	--
4.	Ms. Rina Kumari	Non-Executive Independent Director	--	--
5.	Mr. Hitesh Rijwani	Non-Executive Independent Director	--	--
6.	Mr. Jainil Bhatt	Chief Financial Officer	--	
7.	*Ms. Siddhi Shah	Company Secretary	--	--
8.	*Mr. Chaitra Arora	Company Secretary	--	--

Notes:

***Mr. Hemant A. Parikh ceased to be the Director of the Company with effect from March 17th, 2026.**

*Ms. Siddhi Shah ceased to be the Company Secretary and Compliance Officer of the Company with effect from September 26, 2025.

*Ms. Chaitra Arora ceased to be the Company Secretary and Compliance Officer of the Company with effect from April 30th, 2026.

Accordingly, the percentage increase in their remuneration and ratio of remuneration to the median remuneration is not reported

Notes:

a. Mr. Hitesh Rijwani and Ms. Rina Kumari have been paid sitting fees, not remuneration for the financial year 2025-2026

The remuneration paid to Independent Directors consists of only sitting fees paid to them for attending the meetings of the Board. Hence, the percentage increase of their remuneration has not been considered for the above purpose.

I. Median Remuneration of Employees (MRE) of the Company is Rs. 5,40,000 for the Financial Year 2025-2026. There was no increase in the remuneration during the year.

II. The number of permanent employees on the rolls of the Company is six for the year ended 31st March, 2026.

III. The average percentile increase in the remuneration of employees compared to the increase in remuneration of Key Managerial Personnel is in line with the benchmark study and the performance of the Company over a period of time. There is no exceptional increase in the Remuneration

IV. It is hereby affirmed that the remuneration paid is as per the Remuneration Policy of the Company.

1. During the year under review, the Company has not paid any remuneration to its Directors and Key Managerial
2. Personnel requiring disclosure under Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. Further, there were no employees whose remuneration exceeded the limits prescribed under Rule 5(2) of the said Rules (i.e., ₹1.02 crore per annum or ₹8.5 lakh per month, as applicable).

Place: Ahmedabad
Date: August 17, 2026

For and on behalf of the Board
For, Vivanza Biosciences Limited

Sd/-	Sd/-
Jayendra Mehta	**Sarang Pathak**
Managing Director	Director
DIN:08210602	DIN:02663344

ANNEXURE – E – TO THE DIRECTOR REPORT

FORM NO. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2026

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
Vivanza Biosciences Limited.

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Vivanza Biosciences Limited** (hereinafter called the Company) (CIN:L24110GJ1982PLC005057) having its registered office at **403, Sarthik 2, Opp. Rajpath Club, S. G. Highway Ahmedabad 380054.** Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2026 complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by **Vivanza Biosciences Limited** (the Company) for the financial year ended on 31st March, 2026 according to the provisions of:

I. The Companies Act, 2013 (the Act) and the rules made thereunder;

II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;

III. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

IV. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;

V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-

  (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
  (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

(c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018**; [Not Applicable to the Company during the Audit Period]**

(d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2021;**[Not Applicable to the Company during the Audit Period]**

(e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; **[Not Applicable to the Company during the Audit Period]**

(f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;

(g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; and **[Not Applicable to the Company during the Audit Period]**

(h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **[Not Applicable to the Company during the Audit Period]**

(i) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;

I have also examined compliance with the applicable clauses of the following:

(i) Secretarial Standards issued by The Institute of Company Secretaries of India.

(ii) The Listing Agreements entered into by the Company with Bombay Stock Exchange.

(iii) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc.

A) The Company has maintained a Register of Directors' Attendance as prescribed in the Secretarial Standards.
B) The Directors have signed against their respective names after the meeting has been held.
C) The Company had not received any proxy forms for the Annual General Meeting for the financial year ended 31st March, 2025.
D) The Company has complied with requirements of at least one-third of the total number of directors as independent directors as stated in Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
E) The Company has complied with the of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
F) The Company has obtained all necessary approvals under the various provisions of the Act;
G) There was no prosecution initiated and no fines or penalties were imposed during the year under review under the Act, SEBI Act, SCRA, Depositories Act, Listing Agreement and Rules, Regulations and Guidelines framed under these Acts against / on the Company, its Directors and Officers.

I further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors except as mentioned below.

During the year under review the Company had complied with the all provisions of the section 186 of the Companies Act, 2013, except non charging of interest as per section 186 (7) in respect of some of the loans granted by the Company.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

The following mentioned observations are made:

A) The Directors have complied with the requirements as to disclosure of interests and concerns in contracts and arrangements, shareholdings and directorships in other companies and interests in other entities;

B) The Directors have complied with the disclosure requirements in respect of their eligibility of appointment, their being independent and compliance with the Code of Business Conduct and ethics for Directors and Management Personnel;

I further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period, the Company has no other major / specific events, actions having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc. referred to above viz.

i. Public/Right/Preferential issue of shares / debentures/sweat equity etc.
ii. Redemption / buy-back of securities
iii. Merger / amalgamation / reconstruction etc.
iv. Foreign technical collaborations.

Place: Ahmedabad
Date: August17, 2026

Chintan K. Patel
Practicing Company Secretary
UDIN:A031987H001134121
Mem. No.: A31987
COP No.: 11959
PR No. 2175/2022

ANNEXURE - A to the Secretarial Audit Report

To,
The Members,
Vivanza BiosciencesLimited
Our report of even date is to be read along with this letter.

1. The Management of the company is responsible for maintenance of secretarial records, devise proper system to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.
2. Our responsibility is to express an opinion on these secretarial records and procedures followed by the company with respect to Secretarial Compliances.
3. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
4. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.
5. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
6. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
7. The secretarial Audit Report is neither an assurance as to the future viability of the company nor of the efficacy of effectiveness with which the management has conducted the affairs of the company.

Place: Ahmedabad
Date: August17, 2026

Chintan K. Patel
Practicing Company Secretary
UDIN:A031987H001134121
Mem. No.: A31987
COP No.: 11959
PR No. 2175/2022

ANNEXURE-F TO THE DIRECTORS' REPORT

NON-APPLICABILITY OF SUBMISSION OF REPORT ON CORPORATE GOVERNANCE AS PER EXEMPTION GIVEN IN REGULATION 15(2)(A) OF CHAPTER IV OF SEBI (LODR) REGULATIONS, 2015

To the Members of **VIVANZA BIOSCIENCES LIMITED**

This is to certify that in order to comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with, Regulation 15(2)(a) of Chapter IV of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Paid-up capital of the Company Vivanza Biosciences Limited is not exceeding Rs. 10 Crores i.e. Rs. 4,00,00,000/- (Rupees Four Crore only) and the Net-worth is less than Rs. 25 Crores i.e. Rs. 4,39,53,502/- (Rupees Four Crore thirty Nine Lacs Fifty Three Thousand Five hundred Two only) as on the last day of the previous financial year i.e. 31st March,2026. Therefore, it is not required to submit a Report on Corporate Governance.

Place: Ahmedabad
Date: August 17, 2026

For and on behalf of the Board
For, Vivanza Biosciences Limited

Sd/-	Sd/-
Jayendra Mehta	**Sarang Pathak**
Managing Director	Director
DIN:08210602	DIN:02663344

ANNEXURE- G TO THE DIRECTORS REPORT

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Your Directors have pleasure in presenting the Management Discussion and Analysis Report for the financial year ended 31st March, 2026.

Overview

Vivanza Biosciences Limited is engaged in the Pharmaceuticals and Agro Trading & Consultancy Activities business with a focus on delivering quality healthcare products and solutions. The Company continues to emphasize operational excellence, regulatory compliance, quality assurance, and sustainable growth. During the year under review, the Company remained committed to strengthening its business operations, enhancing customer relationships, and identifying new business opportunities while maintaining prudent financial discipline.

The Management Discussion and Analysis Report provides an overview of the industry scenario, opportunities and threats, risks and concerns, outlook, financial performance and internal control systems of the Company.

Industry Overview

The Indian pharmaceutical industry continues to be one of the fastest-growing sectors globally, supported by strong domestic demand, increasing healthcare awareness, favourable government initiatives and rising exports of pharmaceutical products. India continues to maintain its position as one of the largest suppliers of generic medicines worldwide.

The growth of the pharmaceutical sector is driven by:

- Growing healthcare expenditure and increasing health awareness.
- Expansion of healthcare infrastructure across urban and rural areas.
- Government initiatives promoting affordable healthcare and pharmaceutical manufacturing.
- Increasing demand for quality generic medicines in domestic and international markets.
- Continued investments in research, innovation and digital healthcare technologies.

Despite global economic uncertainties, geopolitical developments and pricing pressures, the Indian pharmaceutical industry continues to demonstrate resilience and offers significant long-term growth opportunities.

Opportunities and Threats

Opportunities

- Expansion of domestic and international pharmaceutical markets.
- Increasing demand for affordable healthcare products.
- Strategic collaborations and contract manufacturing opportunities.
- Adoption of digital technologies and process automation.
- Government support for the pharmaceutical manufacturing ecosystem.

Threats

- Intense competition in domestic and export markets.
- Frequent changes in regulatory requirements.
- Volatility in raw material prices and logistics costs.
- Foreign exchange fluctuations impacting export competitiveness.
- Global economic uncertainties affecting demand and supply chains.

Risk Factors and Concerns

Regulatory Risk

The pharmaceutical industry operates under stringent regulatory requirements. The Company continuously monitors changes in applicable laws and regulations and ensures compliance through established internal processes.

Market Competition

The Company operates in a highly competitive environment. Continuous product quality improvement, customer satisfaction and efficient cost management remain key focus areas to maintain competitiveness.

Supply Chain Risk
The Company monitors procurement and inventory management closely to minimize disruptions arising from fluctuations in the availability and pricing of raw materials.
Financial Risk
The Company is exposed to risks arising from changes in interest rates, credit risk and foreign exchange fluctuations. Appropriate financial controls and monitoring mechanisms are in place to manage these risks.
Internal Control Systems and Their Adequacy
The Company has an adequate system of internal financial controls commensurate with the size and nature of its business. These controls ensure safeguarding of assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records and timely preparation of reliable financial information.
The Audit Committee periodically reviews the adequacy and effectiveness of the internal control systems and recommends corrective actions wherever considered necessary.
Human Resources
The Company recognizes that its employees are its most valuable asset. It continues to focus on employee development through training, skill enhancement and maintaining a healthy and safe work environment. Industrial relations remained cordial throughout the financial year.
Future Outlook
The Company remains optimistic about the long-term growth prospects of the pharmaceutical industry. It will continue to focus on:

- Expanding its product portfolio.
- Strengthening operational efficiencies.
- Enhancing quality standards and regulatory compliance.
- Exploring strategic alliances and new business opportunities.
- Improving customer satisfaction and sustainable profitability.

The management remains committed to creating long-term value for all stakeholders through disciplined execution of business strategies.

DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE
The **Revenue from Operations** for the financial year 2025-26 stood at **Rs. 11,234.04 Lakhs**, as compared to **Rs. 297.74 Lakhs** in the previous financial year, reflecting substantial growth in the Company's business activities.
The Company reported a **Net Profit of Rs. 37.50 Lakhs** during the financial year 2025-26 as against a **Net Loss of Rs. 69.51 Lakhs** in the previous financial year. The turnaround in profitability was primarily driven by increased business volumes, improved operational efficiency, better cost management and focused market initiatives.
The management remains committed to sustaining this growth momentum by strengthening its product portfolio, improving operational excellence, exploring new business opportunities, and creating long-term value for all stakeholders.

Place: Ahmedabad
Date: August 17, 2026

For and on behalf of the Board
For, Vivanza Biosciences Limited

Sd/-	Sd/-
Jayendra Mehta	**Sarang Pathak**
Managing Director	Director
DIN:08210602	DIN:02663344

Independent Auditor’s Report

To
The Members of
Vivanza Biosciences Limited

Opinion

We have audited the accompanying financial statements of Vivanza Biosciences Limited (“the Company”), which comprise the balance sheet as at March 31, 2026, and the Statement of Profit and Loss and statement of cash flows for the year ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.
In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the (‘Act’) in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, its **Profit** and cash flows for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the annual standalone financial statements for the year ended March 31, 2026. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that give a true and fair view of the Profit or loss and other comprehensive income and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations, This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to these financial results, in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and of its Joint Venture to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on other Legal and Regulatory Requirements

1. As required by the Companies (Auditor’s Report) Order, 2020 (“the Order”) issued by the Central Government in terms of Section 143 (11) of the Act, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by section 143(3) of the Act, we report that:

a) We have sought and obtained all the information and an explanation which is to the best of our knowledge and beliefs were necessary for the purposes of our audit
b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.
c) The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standard) Rules, 2015, as amended
e) On the basis of written representations received from the directors as on 31 March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026, from being appointed as a director in terms of Section 164(2) of the Act.
f) With respect to the other matters included in the Auditor's Report and to our best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position.
ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
iii. There is no amount required to be transferred, to the investor's education & Protection Fund by the Company.

Based on our examination, which included test checks, the Company has used accounting softwares for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the softwares. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2026.

For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

CA Shivam Soni
Proprietor
Membership No: 178351
UDIN:26178351EMKFBH6295

Place: Ahmedabad
Date: 7th May, 2026

Annexure A to the Independent Auditors' Report on the financial statements of Vivanza Biosciences Limited for the year ended 31 March 2026

To,
The Members of Vivanza Biosciences Limited

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

(I) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
(B) The Company has maintained proper records showing full particulars of Intangibleassets.

(b) Property, Plant and Equipment were physically verified by the management in accordance with a planned programme of verifying them at reasonable intervals having regard to the size of the Company and the nature of its assets.

(c) The title deeds of all the immovable properties (other than properties where the Company is the lessee, and the lease agreements are duly executed in favor of the lessee) are held in the name of the Company.

(d) The Company has not revalued its Property, Plant and Equipment (including Right of use asset) or intangible assets during the year ended March 31, 2026.

(e) There are no proceedings initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a) The management has conducted physical verification of inventory at reasonable intervals during the year. In our opinion the coverage and the procedure of such verification by the management is appropriate. Discrepancies of 10% or more in aggregate for each class of inventory were not noticed on such physical verification.

(b) The Company has not been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. Therefore, the requirement to report on clause 3(ii)(b) of the Order is not applicable to the Company.

(iii) (a) During the year the Company has provided loans, advances in the nature of loans, provided guarantee and security to companies as follows:

Particulars	**Loans (In Lakhs)**
Aggregate amount granted/ provided during the year,	
- Subsidiaries	1.21/-
- Related Parties	-
- Others	-
Balance outstanding as at balance sheet date in respect of above case,	
- Subsidiaries	-
- Related Parties	0.80/-
- Others	-

(b) During the year the investments made and the terms and conditions of the grant of allloans and advances in the nature of loan during the year are, prima facie, notprejudicial to the Company's interest.

(c) The company has granted interest free loan which is violation of the Act.

(d) There are no amounts of loan granted to companies which are overdue for more than ninety days.

(e) There were no loans which had fallen due during the year, that have been renewed or extended or fresh loans granted to settle the overdue of existing loans given to the same parties.

(f) The Company has not granted any loans or advances in the nature of loans, either repayable on demand or without specifying any terms or period of repayment to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(f) of the Order is not applicable to the company.

(iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any guarantee or security as specified under Section 185 of the Companies Act, 2013 and the Company has not provided any guarantee or security as specified under Section 186 of the Companies Act, 2013. Further, the Company has complied with the provisions of Section 186 of the Companies Act, 2013 in relation to loans given and investments made.

(v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under section 148(1) of the Companies Act, 2013, related to the manufacturing activities and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.

(vii)(a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST. According to the information and explanations given to us and based on audit procedures performed by us, no undisputed amounts payable in respect of these statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.

(b) The Company is regularly depositing with appropriate authorities undisputed statutory dues. Therefore, the requirement to report on clause 3(v) of the Order is not applicable to the Company.

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.

(b) The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.

(c) According to the information and explanations given to us by the management, the Company has not obtained any term loans during the year. Accordingly, clause 3(ix)(c) of the Order is not applicable.

(d) On an overall examination of the standalone financial statements of the Company, no funds raised on short-term basis have been used for long-term purposes by the Company.

(e) On an overall examination of the standalone financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.

(f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies. Hence, the requirement to report on clause (ix)(f) of the Order is not applicable to the Company.

(x) (a) The Company has not raised any money during the year by way of initial public offer/further public offer (including debt instruments) hence, the requirement to report on clause 3(x)(a) of the Order is not applicable to the Company.

(b) The Company has not made any preferential allotment or private placement of shares/fully or partially or optionally convertible debentures during the year under audit and hence, the requirement to report on clause 3(x)(b) of the Order is not applicable to the Company

(xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) During the year, no report under sub-section (12) of section 143 of the Companies Act, 2013 has been filed by cost auditor and secretarial auditor or by us in Form ADT– 4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) We have taken into consideration the whistle blower complaints received by the Company during the year while determining the nature, timing and extent of our audit procedures.

(xii) The Company is not a Nidhi Company as per the provisions of the Companies Act, 2013. Therefore, the requirement to report on clause 3(xii)(a),(b) and (c) of the Order is not applicable to the Company.

(xiii) Transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the standalone financial statements, as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.

(b) Internal audit under section 138 of Companies Act, 2013 is not applicable.Therefore, the requirement to report on clause 3(xiv)(b) of the Order is not applicable to the Company.

(xv) The Company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence requirement to report on clause 3(xv) of the Order is not applicable to the Company.

(xvi) The provisions of section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause (xvi)(a), (b), (c) & (d) of the Order is not applicable to the Company.

(xvii) The Company has not incurred cash losses in the current year and in the immediatelypreceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year and accordingly the requirement to report on Clause 3(xviii) of the Order is not applicable to the Company.

(xix) On the basis of the ageing report, financial ratios and expected dates of realization of financial assets and payment of financial liabilities, any other information accompanying the financial statements, Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company.

(xx) Corporate social responsibility under section 135(5) of Companies Act, 2013 is not applicable to the Company. Therefore, the requirement to report on clause 3(xx)(a) and 3(xx)(b) of the Order is not applicable to the Company.

For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

CA Shivam Soni
Proprietor
Membership No: 178351
UDIN:26178351EMKFBH6295

Place: Ahmedabad
Date: 7th May, 2026

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **M/S. Vivanza Biosciences Limited** (“the Company”) as of March 31, 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026.

For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

CA Shivam Soni
Proprietor
Membership No: 178351
UDIN:26178351EMKFBH6295

Place: Ahmedabad
Date: 7th May, 2026

VIVANZA BIOSCIENCES LIMITED
(CIN:L24110GJ1982PLC005057)
STANDALONE BALANCE SHEET AS AT 31/03/2026
(Rs. in Lakhs)

Particulars	Note No.	As at 31st March,2026	As at 31st March,2025
I. ASSETS			
1 Non Current Asset			
(a) Property, Plant and Equipment	1	12.31	2.06
(b) Capital Work-In-Progress		-	-
(c) Other Intangible Asset		-	-
(d) Financial Asset			
(i) Investments	2	191.45	191.45
(ii) Other Non current Financial Assets	3	59.33	59.33
(e) Deferred Tax Assets(Net)		-	0.06
Total Non-Current Assets		263.09	252.91
2. Current Assets			
(a) Inventories	4	294.51	184.25
(b) Financial Assets			
(i) Trade Receivables	5	1,066.01	738.59
(ii) Cash And Cash Equivalent	6	1.78	4.94
(iii) Loan & Advances	7	162.60	180.49
(c) Other Current Asset	8	34.56	30.03
Total Current Assets		1,559.47	1,138.31
Total Assets		1,822.56	1,391.22
II. Equity & liabilities			
1. Equity			
(a) Equity Share Capital	9	400.00	400.00
(b) Other Equity	10	39.54	2.04
Total Equity		439.54	402.04
2. Liabilities			
(a) Non Current Liabilities			
(i) Borrowings	11	87.72	77.53
(ii) Deferred Tax Liabilities		0.02	-
(iii) Other Non-Current Liabilities		-	-
(b) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	12	662.18	531.73
(ii) Trade Payables	13	606.87	321.80
(iii) Other Financial Liabilities		-	-
(b) Other Current Liabilities	14	10.52	54.33
(c) Short Term Provision	15	15.71	3.80
Total Liabilities		1,383.02	989.18
Total Equity & liabilities		1,822.56	1,391.22

Contingent Liabilities & Commitments Nil

For, Vivanza Biosciences Limited

For, SHIVAM SONI & Co.
Chartered Accountants
FRN : 152477W

Jayendra Mehta
Managing Director
DIN : 08210602

Sarang Pathak
Director
DIN : 02663344

Jainil Bhatt
CFO

CA Shivam Soni
Proprietor
Membership No. 178351
UDIN: 26178351EMKFBH6295

Place : Ahmedabad
Date : 07/05/2026

VIVANZA BIOSCIENCES LIMITED
STANDALONE STATEMENT OF PROFIT & LOSS ACCOUNT FOR THE PERIOD FROM 01-04-2025 TO 31-03-2026

(Rs. in Lakhs)

	Particulars	Note No.	2025-26	2024-25
I	Revenue From Operations	16	11,223.10	294.28
II	Other Income	17	10.94	3.46
III	Total Income (I+II)		11,234.04	297.74
IV	Expenses			
	Purchase of Stock in Trade	18	11,207.08	266.77
	Changes in Inventories	19	(110.25)	(4.29)
	Employee Benefit Expenses	20	33.08	36.73
	Finance Costs	21	27.92	35.08
	Depreciation & Amortisation Expenses		2.16	1.40
	Other Expenses	22	22.27	31.42
	Total Expenses		11,182.25	367.10
V	Profit Before Exceptional & Extraordinary Items & Tax (III-IV)		51.79	(69.36)
VII	Exceptional Items		-	-
VIII	Profit Before Extraordinary Items & Tax		51.79	(69.36)
	Extraordinary Items		-	-
IX	Profit Before Tax		51.79	(69.36)
X	Tax Expenses			
	Current Tax		14.20	-
	Deferred Tax		0.09	0.14
XI	Profit/(Loss) for the period from Continuing Operations(IX-X)		37.50	(69.51)
XII	Profit/(Loss) from Discontinuing Operations			
XIII	Tax Expense of Discontinuing Operations			
XIV	Profit/(Loss) from Discontinuing Operations (after tax)(XII-XIII)		-	-
XV	Profit/(Loss) for the Period(XI+XIV)		37.50	(69.51)
	Other Comprehensive Income			
	Items that will not be reclassified to profit or loss		-	-
	Total comprehensive income for the year, net of tax		37.50	(69.51)
XVI	Earning Per Equity Share			
	Basic		0.09	(0.17)
	Diluted		0.09	(0.17)

The Notes referred to above form an integral part of the Balance Sheet

For, Vivanza Biosciences Limited

For, SHIVAM SONI & Co.
Chartered Accountants
FRN : 152477W

Jayendra Mehta
Managing Director
DIN : 08210602

Sarang Pathak
Director
DIN : 02663344

Jainil Bhatt
CFO

CA Shivam Soni
Proprietor
Membership No. 178351
UDIN: 26178351EMKFBH6295

Place : Ahmedabad
Date : 07/05/2026

VIVANZA BIOSCIENCES LIMITED

(CIN:L24110GJ1982PLC005057)

STANDALONE CASHFLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH, 2026

(Rs. in Lakhs)

Particulars	2025-26	2024-25
A Cash flow from Operating Activities		
Net Profit Before Tax	51.79	(69.36)
Adjustments for:		
Add Depreciation	2.16	1.40
Less Dividend Income	-	-
Add Prelimnary Expenses Written Off	-	-
Add Interest Expenses	27.92	35.08
Add Sundry bal Writeoff	-	-
Add Loss on sale of car	-	-
Add Share Listing & Processing Fees		
Less Short Term Capital Gain (Mutual Fund)	-	-
Operating Profit / (Loss) before Working Capital Changes	81.86	(32.89)
Adjustments for:		
Increase/(Decrease) in Trade Payables	285.07	(501.67)
Increase/(Decrease) in other current liabilities	(43.80)	12.03
Increase/(Decrease) in provisions	11.91	(19.72)
(Increase)/Decrease in Trade Receivables	(327.42)	298.08
(Increase)/Decrease in inventories	(110.25)	(4.29)
(Increase)/Decrease in other current assets	(4.53)	1.57
Cashflow generated from Operating Activities	(107.16)	(246.88)
Income Tax Paid (Net of Refund)	14.20	-
Net Cashflow generated from Operating Activities A	(121.36)	(246.88)
B Cash flow from Investment Activities		
Purchase of Property, Plant and Equipment	(12.40)	(0.79)
Sale of Investments	-	-
Purchase of Investments	-	-
Shares Issued	-	-
Dividend Income	-	-
Net Cashflow generated from Investments Activities B	(12.40)	(0.79)
C Cash flow from Financiang Activities		
Share Listing & Processing Fees	-	-
Interest Expenses	(27.92)	(35.08)
(Increase)/Decrease in other non-current assets		
(Increase)/Decrease in short term loans & advances	17.88	(4.34)
Increase /(Decrease) in Borrowings (Liabilities)	140.64	282.98
Net Change in Unsecured Loans Taken	-	-
Movement in Loans & Advances Granted	-	-
Net Cashflow generated from Financing Activities C	130.61	243.57
Net Change in Cash & Cash Equivalents (A+B+C)	(3.16)	(4.11)
Opening Cash & Cash Equivalents	4.94	9.05
Closing Cash & Cash Equivalents	1.78	4.94

Notes:1. Previous year's figures have been regrouped wherever necessary, to conform to this year's classification.

For, Vivanza Biosciences Limited

Jayendra Mehta
Managing Director
DIN : 08210602

Sarang Pathak
Director
DIN : 02663344

Jainil Bhatt
CFO

Place : Ahmedabad
Date : 07/05/2026

For, SHIVAM SONI & Co.
Chartered Accountants
FRN : 152477W

CA Shivam Soni
Proprietor
Membership No. 178351
UDIN: 26178351EMKFBH6295

VIVANZA BIOSCIENCES LIMITED
(CIN:L24110GJ1982PLC005057)
STANDALONE STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED MARCH 31, 2026

A. Equity Share Capital

(Rs. in Lakhs)

Particulars	No. of share	Amount
Equity share capital of face value Rs. 1/- each		
Balance as at April 1, 2023	4,00,00,000.00	400.00
Equity share capital of face value Rs. 1/- each		
Balance as at April 1, 2024	4,00,00,000.00	400.00
Equity share capital of face value Rs. 1/- each	-	-
Balance as at March 31, 2025	4,00,00,000.00	400.00
Equity share capital of face value Rs. 1/- each		
Balance as at March 31, 2026	4,00,00,000.00	400.00

B. Other Equity

(Rs. in Lakhs)

Particulars	Reserves and Surplus	Total
	Retained Earnings	
Balance as at 1st April, 2024	71.54	71.54
Profit / (Loss) for the year	(69.51)	(69.51)
Balance as at March 31, 2025	2.04	2.04
Profit / (Loss) for the year	37.50	37.50
Other comprehensive income	-	-
Total Comprehensive Income / (loss) for the year	37.50	37.50
Balance as at March 31, 2026	39.54	39.54

See accompanying notes to the financial statements
In terms of our report attached

For, Vivanza Biosciences Limited

Jayendra Mehta
Managing Director
DIN : 08210602

Sarang Pathak
Director
DIN : 02663344

Jainil Bhatt
CFO

Place : Ahmedabad
Date : 07/05/2026

For, SHIVAM SONI & Co.
Chartered Accountants
FRN : 152477W

CA Shivam Soni
Proprietor
Membership No. 178351
UDIN: 26178351EMKFBH6295

1 PROPERTY, PLANT AND EQUIPMENT

(Rs. in Lakhs)

Particulars	Gross Block						Depreciation				Net Block	
	As at 01/04/2025	Addition due to Demerger	Addition	Deduction	Acquire through Business Combination	As at 31/03/2026	As at 01/04/2025	Depreciation Charge	Deduction	As at 31/03/2026	As at 31/03/2026	As at 31/03/2025
TV	1.15	-	-	-	-	1.15	0.57	0.09	-	0.66	0.50	0.58
Projector	2.03	-	-	-	-	2.03	1.26	0.75	-	2.01	0.02	0.77
Audio Speakers	0.68	-	-	-	-	0.68	0.42	0.25	-	0.67	0.01	0.26
Laptop	2.39	-	-	-	-	2.39	2.27	0.02	-	2.29	0.10	0.12
Mobile	0.41	-	-	-	-	0.41	0.07	0.02	-	0.09	0.32	0.34
Car	-	-	12.40	-	-	12.40	-	1.03		1.03	11.37	-
Total Tangible Assets	6.65	-	12.40	-	-	19.05	4.59	2.16	-	6.74	12.31	2.06
Previous Year	5.86	-	0.79	-	-	6.65	3.19	1.40	-	4.59	2.06	2.67

VIVANZA BIOSCIENCES LIMITED
(CIN:L24110GJ1982PLC005057)
NOTES TO THE FINANCIAL STATEMENTS

2 Non-current Investments (Rs. in Lakhs)

Particulars	As at 31st March,2026	As at 31st March,2025
Other Investments - Un Quoted	0.25	0.25
(1) Investment in Equity Shares		
Equity Shares of Rs. 10/- each of J.V.N.S. Bank Limited	0.25	0.25
Equity Shares of Rs. 19.12/- each of Vivanza Lifesciences Pvt Ltd	191.20	191.20
Total	191.45	191.45
Market Value of the Quoted Shares		
Market Value of the Un Quoted Shares	191.45	191.45

3 Other Non current Financial Assets

Particulars	As at 31st March,2026	As at 31st March,2025
Recoverable in Cash or Kind	59.33	59.33
Balance with Government Authorities Central excise	0.00	0.00
Total	59.33	59.33

4 Inventory

Particulars	As at 31st March,2026	As at 31st March,2025
Stock In Trade	294.51	184.25
Total	294.51	184.25

5 Trade Receivables

Particulars	As at 31st March,2026	As at 31st March,2025
	527.68	85.21
Outstanding for less than 6 months from the due date Unsecured, considered good	-	
	538.34	653.39
Outstanding for more than 6 months from the due date Unsecured, considered good	-	
Total	1,066.01	738.59

Trade Receivables ageing schedule *

Particulars	As at 31st March,2026 Outstanding for following periods from due date of payment					
	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 year	Total
Undisputed Trade Receivable- considered good	515.19	313.29	-	-	237.53	1,066.01
Undisputed Trade Receivable- considered doubtful	-		-	-	-	-
Disputed Trade Receivable- considered good	-		-	-	-	-
Disputed Trade Receivable- considered doubtful	-		-	-	-	-

Trade Receivables ageing schedule *

Particulars	As at 31st March,2025 Outstanding for following periods from due date of payment					
	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 year	Total
Undisputed Trade Receivable- considered good	85.21	134.69	262.46	106.51	149.73	738.59
Undisputed Trade Receivable- considered doubtful	-		-	-	-	-
Disputed Trade Receivable- considered good	-		-	-	-	-
Disputed Trade Receivable- considered doubtful	-		-	-	-	-

6 Cash & Cash Equivalents

Particulars	As at 31st March,2026	As at 31st March,2025
Balances with Banks	0.29	0.00
In Current Account	0.29	0.00
In Fixed Deposits held as margin money	-	-
Cash on Hand	1.49	4.94
Total	1.78	4.94

7 Loans

Particulars	As at 31st March,2026	As at 31st March,2025
Other Loans & Advances		
Unsecured, Considered good		
Loan to Corporate Bodies	15.00	15.00
Loan to Related Parties	110.09	130.17
	-	
Other Loans	19.74	17.87
VAT Credit	-	-
GST Credit	17.57	17.18
TDS & TCS Credit	-	0.07
VAT & CST Deposit	0.20	0.20
Advance for Goods	-	-
Total	162.60	180.49

8 Other Current Assets

Particulars	As at 31st March,2026	As at 31st March,2025
Prelimnary & Preoperative Expenses	-	-
Public Issue Expenses	-	-
Balance With Government Authorities (TDS/TCS)	6.47	-
Balance With Government Authorities (GST)	4.07	-
Other Deposit	2.89	2.89
Advances to Trade Payble	21.13	27.14
Total	34.56	30.03

9 Equity Share Capital

9.1 Authorized, Issued, Subscribed and Paidup share capital

Particulars	As at 31st March,2026	As at 31st March,2025
	Amount	Amount
Authorised Share Capital		
4,00,00,000 Equity Shares of Rs. 1 Each	400.00	400.00
Total	400.00	400.00
Issued Share Capital		
4,00,00,000 Equity Shares of Rs. 1 Each	400.00	400.00
Total	400.00	400.00
Subscribed & Fully Paid		
4,00,00,000 Equity Shares of Rs. 1 Each	400.00	400.00
Total	400.00	400.00

9.2 Details of the Shares for the Preceding Five Years

Particulars	01-04-2021 to 31-03-2026
Number of Equity Shares Bought Back	-
Number of Preference Shares Reedeemed	-
Number of Equity Share Issue as Bonus Share	-
Number of Preference Share Issue as Bonus Share	-
Number of Equity Shares Allotted For Contracts	-
Without Payment Received In Cash	-
Number of Preference Shares Allotted For Contracts	-
Without Payment Received In Cash	-

9.3 Reconciliation of Share Capital

Particulars	As at 31st March,2026		As at 31st March,2025	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares				
(Face Value Rs. 1)				
Shares Outstanding at the Beginning	4,00,00,000.00	400.00	4,00,00,000.00	400.00
Shares cancelled during the year		-	-	-
Shares issued during the year(Under		-	-	-
Shares issued during the year(Against		-	-	-
Shares Outstanding at the End of the	4,00,00,000.00	400.00	4,00,00,000.00	400.00

9.4 Share Holders Holding More than 5% Share

Name of the Share Holders	As at 31st March,2026		As at 31st March,2025	
	No. of Shares	% of Holding	No. of Shares	% of Holding
PARTH HEMANT PARIKH	1,71,95,510.00	42.99	1,71,95,510.00	42.99
HEMANT PARIKH	1,00,211.00	0.25	1,00,211.00	0.25
ASHOKA METCAST LIMITED	15,39,259.00	3.85	77,49,088.00	19.37
ARDENT VENTURES LLP	92,37,000.00	23.09	92,37,000.00	23.09

9.5 Shares held by Promoters at the end of the year

Name of the Promoter	As at 31st March,2026		As at 31st March,2025		% Change during the year
	No. of Shares	% of total share	No. of Shares	% of total share	
PARTH HEMANT PARIKH	1,71,95,510.00	42.99	1,71,95,510.00	42.99	-
HEMANT PARIKH	1,00,211.00	0.25	1,00,211.00	0.25	-

10 Other Equity

Particulars	As at 31st March,2026	As at 31st March,2025
Profit & Loss A/c		
Opening balance	2.04	71.54
(+) Amount of Share Capital	-	-
(+) Transfer of Current Year Profit	37.50	(69.51)
Closing balance	39.54	2.04
Total	39.54	2.04

11 Non-Current Borrowings

Particulars	As at 31st March,2026	As at 31st March,2025
Secured Loans		
From Banks	10.19	
Unsecured Loans repayable on Demand		
Loan From Relatives of Directors & Other Companies	17.53	17.53
Other Borrowing	60.00	60.00
Total	87.72	77.53

12 Current Borrowings

Particulars	As at 31st March,2026	As at 31st March,2025
Unsecured Loans repayable on Demand		
Loan From Relative of Directors & Other Companies	525.56	344.35
SBI CC A\C	136.62	187.38
Other Borrowings	-	-
Total	662.18	531.73

13 Trade Payables

Particulars	As at 31st March,2026	As at 31st March,2025
Unsecured Loans repayable on Demand		
Due to Micro & Small Enterprises	-	-
Others	606.87	321.80
Total	606.87	321.80

The Company has not received any intimation on suppliers regarding their status under the Micro, Small and Medium Enterprise Development (MSMED) Act, 2006 and hence disclosure as required under section 22 of The Micro, Small and Medium Enterprise regarding:
(a) Amount due and outstanding to suppliers as at the end of the accounting year;
(b) interest paid during the year;
(c) interest payable at the end of the accounting year;
(d) interest accrued and unpaid at the end of the accounting year; have not been given , the company is making efforts to get the confirmation from the suppliers as regards their status under the said act.

13.1 *Trade Payables ageing schedule

Particular	As at 31st March,2026				
	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
MSME	-	-	-	-	-
Others**	579.32	3.32	23.90	0.33	606.87
Disputed dues MSME	-	-	-	-	-
Disputed dues Others	-	-	-	-	-
Total					606.87

*Trade Payables ageing schedule

Particular	As at 31st March,2025				
	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
MSME	-	-	-	-	-
Others**	90.34	226.21	4.74	0.51	321.80
Disputed dues MSME	-	-	-	-	-
Disputed dues Others	-	-	-	-	-
Total					321.80

14 Other Current Liabilities

Particulars	As at 31st March,2026	As at 31st March,2025
Statutory Dues	8.14	0.08
Other Payables	-	0.08
Advance from Trade receivable	2.38	54.16
Total	10.52	54.33

15 Short term provisions

Particulars	As at 31st March,2026	As at 31st March,2025
Unpaid Legal Fees	-	-
Unpaid Audit Fees	-	0.50
Salary Payable	0.76	2.55
Income Tax Provision	14.95	0.75
Total	15.71	3.80

16 Revenue from Operations

Particulars	2025-26	2024-25
GST Taxable Supply	10,138.08	173.32
GST NIL Rates Supply	1,085.03	120.96
Exempt Supply	-	-
Technical Dossier Fee	-	-
Total	11,223.10	294.28

17 Other Income

Particulars	2025-26	2024-25
Discount Income (Kasar)	0.62	-
Other Income	2.65	2.13
Transportation receivable	-	-
Income tax Refund	-	-
Interest on Income tax refund	-	-
Duty Drawback	-	1.33
Assets & Liabilities W.Off	7.67	-
Total	10.94	3.46

18 Purchase of Stock in Trade

Particulars	2025-26	2024-25
GST Taxable Purchase	11,207.08	266.77
GST Exempt Purchase	-	-
Total	11,207.08	266.77

19 Change in Inventory

Particulars	2025-26	2024-25
(A) Opening Stock	184.25	179.96
Finished Goods		
(1) Cattle Feed (Cemex)	24.96	24.96
(2) I V Fluid	-	-
(3) Pharma	40.93	36.64
(4) Real Cow Ghee	-	-
(B) Opening Stock of Branch Delhi	118.37	118.37
(A) Closing Stock	294.51	184.25
Finished Goods		
(1) Cattle Feed (Cemex)	24.96	24.96
(2) I V Fluid	-	-
(3) Pharma	151.18	40.93
(4) Real Cow Ghee	-	-
(B) Closing Stock of Branch Delhi	118.37	118.37
Total	(110.25)	(4.29)

20 Employee Benefit Expenses

Particulars	2025-26	2024-25
Directors Remuneration	-	-
Salary & Wages	33.08	36.73
Total	33.08	36.73

21 Finance Costs

Particulars	2025-26	2024-25
Interest Expense	27.92	35.08
Total	27.92	35.08

22 Other Expenses

Particulars	2025-26	2024-25
Payment to Auditors *	0.50	-
Advertisement Expenses	0.57	0.39
Analytical Expenses	-	-
Bank Charges	0.41	0.28
Bonus	-	-
Business Pramotion Exp.	-	-
Discount	-	2.51
E Voting Charges	-	0.06
Electricity Exp	-	-
Foreign Exchange Loss	0.49	0.91
Freight Expenses	7.32	11.53
Import-Export Charges	2.77	0.50
Insurance Expenses	0.24	0.23
Legal & Professional Charges	3.39	3.27
Loan Processing Fees	-	-
Share Certificate Expenses	-	0.18
Office Expenses	0.16	0.14
Inspection And Testing Charges	0.51	
Other Miscellaneous Expenses	1.70	2.32
Packing Expenses	-	0.05
Postage & Courier	0.01	0.21
Preliminary expenses W/off	-	3.68
Printing & Stationary Expenses	0.99	0.59
Rent Expenses	-	-
Share Registrar Fees	0.84	
Share Listing & Processing Fees	1.75	3.82
Die Punch Expense	-	-
Software Licence Fees	0.03	0.03
Transportation Expenses	0.59	0.73
Travelling Expenses	-	-
Total	22.27	31.42

* Payment to Auditors		
For Audit Fees	0.50	-
For Others	-	-

➢ Significant Accounting Policies

- **Company Overview**
  Vivanza Biosciences Limited ("the company") is a listed company domiciled in India and incorporated under the provisions of the Companies Act, 1956. The company is engaged in the business of Pharmaceutical Products. The company is listed on the Bombay Stock Exchange.

- **Statement of Compliance**
  The Standalone Financial Statements comply, in all material aspects, with Indian Accounting Standards ('Ind AS') notified under Section 133 of the Companies Act, 2013 ('the Act') read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and other relevant provisions of the Act.
  Accordingly, the Company has prepared these Standalone Financial Statements which comprise theBalance Sheet as at 31 March 2026, the Statement of Profit and Loss, the Statement of Cash Flows and the Statement of Changes in Equity for the year ended as on that date, and accounting policies and other explanatory information.

- **Basis for Preparation and Presentation**
  The Standalone Financial Statements have been prepared on the historical cost basis, except forcertain financial instruments and defined benefit plans which are measured at fair value at the end of each reporting period. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
  All assets and liabilities have been classified as current or non-current as per the Company'snormal operating cycle and other criteria set out in the Schedule III to the Act.

- **Current versus non-current classification**
  The Company presents assets and liabilities in the balance sheet based on current/non-currentclassification. An asset is classified as current when it satisfies any of the following criteria:
  - It is expected to be realised in, or is intended for sale or consumption in, the Company's normal operating cycle. it is held primarily for the purpose of being traded;
  - it is expected to be realised within 12 months after the reporting date; or
  - It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

  All other assets are classified as non-current.
  A liability is classified as current when it satisfies any ofthe following criteria:
  - it is expected to be settled in the Company's normaloperating cycle;
  - it is held primarily for the purpose of being traded;
  - it is due to be settled within 12 months after thereporting date; or the Company does not have anunconditional right to defer settlement of the liabilityfor at least 12 months after the reporting date

  Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.
  All other liabilities are classified as non-current.
  Deferred tax assets and liabilities are classified as non-current assets and liabilities.

- **Financial Instruments**
  Financial assets and financial liabilities are recognized when an entity becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss.

- **Financial Assets**
  - **Classification**
    The Company classifies its financial assets in the following measurement categories:
    - Those to be measured subsequently at fair value (either through OCI, or through profit orloss), and
    - Those measured at amortized cost.
    - Those measured at carrying cost for equity instruments subsidiaries and joint ventures.
  - **Initial recognition and measurement**
    All financial assets, are recognized initially at fair value

- **Financial liabilities and equity instruments**

Classification as debt or equity
Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangement.
An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs.

Equity instruments

The Company subsequently measures all equity investments at fair value. Where the Company's management has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to the Standalone Statement of Profit and Loss. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified to equity. Dividends from such investments are recognized in the Standalone Statement of Profit and Loss within other income when the Company's right to receive payments is established. Impairment losses (and reversal of impairment losses) on equity investments measured at FVTOCI are not reported separately from other changes in fair value

Financial liabilities
The Company's financial liabilities comprise borrowings, trade payables and other liabilities.These are initially measured at fair value, net of transaction costs, and are subsequently measured at amortized cost using the effective interest method or at FVTPL. The EIR is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period at effective interest rate. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period.

Financial liabilities at amortized cost
Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortized cost at the end of subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortized cost are determined based on the

effective interest method. Interest expense that is not capitalized as part of costs of an asset is included in the 'Finance costs' line item.
Trade and other payables are recognized at the transaction cost, which is its fair value.

Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the financial asset or settle the financial liability takes place either:

- In the principal market, or
- In the absence of a principal market, in the most advantageous market

  The principal or the most advantageous market must be accessible by the Company. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest andbest use.

Revenue recognition

The Company has adopted Ind AS 115 from 1st April, 2018 and opted for modified retrospective application with the cumulative effect of initially applying this standard recognised at the date of initial application. The standard has beenapplied to all open contracts as on 1st April, 2018, and subsequent contracts with customers from that date.
Performance obligation:

The revenue is recognized on fulfillment of performance obligation.

Sale of products:

The Company earns revenue primarily from sale of Steel Product and Trading in goods.

Payment for the sale is made as per the credit terms in the agreements with the customers. The credit period isgenerally short term, thus there is no significant financing component.

The Company's contracts with customers do not provide for any right to returns, refunds or similar obligations.The Company's obligation to repair or replace faulty products under standard

warranty terms is recognised as aprovision.

Revenue is recognised when the performance obligations are satisfied and the control of the product is transferred,being when the goods are delivered as per the relevant terms of the contract at which point in time the Company hasa right to payment for the asset, customer has possession and legal title to the asset, customer bears significant riskand rewards of ownership and the customer has accepted the asset or the Company has objective evidence that allcriteria for acceptance have been satisfied.

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. Interest income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization

Taxation

Tax on Income comprises current and deferred tax. It is recognized in statement of profit and loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive income.

Current tax

Tax on income for the current period is determined on the basis on estimated taxable income and tax credits computed in accordance with the provisions of the relevant tax laws and based on the expected outcome of assessments / appeals. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred tax

Deferred tax is recognized for the future tax consequences of deductible temporary differences between the carrying values of assets and liabilities and their respective tax bases at the reporting date, using the tax rates and laws that are enacted or substantively enacted as on reporting date. Deferred tax assets are recognized to the extent that it is probable that future taxable income will be available against which the deductible temporary differences can be utilized. Deferred tax relating to items recognized outside the statement of profit and loss is recognized outside the statement of profit and loss, either in other comprehensive income or directly in equity. The carrying amount of deferred tax assets is reviewed at each reporting date.

Earnings per share

The Company presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic earnings per share is computed by dividing the profit or loss after tax by the weighted average numberof equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for treasury shares, bonus issue, bonus element in a rights issue to existing shareholders, share split and reverse share split (consolidation of shares).

Diluted earnings per share is computed by dividing the profit/(loss) after tax as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares including the treasury shares held by the Company to satisfy the exercise of the share options by the employees.

- **Foreign exchange transactions**

  Foreign exchange transactions are recorded using the exchange rates prevailing on the dates of the respective transactions. Exchange differences arising on foreign exchange transactions settled during the year are recognized in the statement of profit and loss for the year.

(In Lakhs)

Particulars	**2025-26**	**2024-25**
Foreign Exchange Earning	668.36	120.96
Foreign Exchange Outgo	0	0

24. Notes on Accounts

- **Contingent Liabilities**
  There is no contingent liability as informed by management.

- **Capital Expenditure Commitments:** Nil

- **Related Party Transactions:-**
  As per Indian Accounting Standard (Ind AS -24) issued by the Institute of Chartered Accountants of India, the disclosures of transactions with the related parties are given below:
  List of related parties where control exists and related parties with whom transactions have taken place and relationships:

Sr. No.	Name	Relationship
1	Jayendra Mehta	Managing Director
2	Sarang B Pathak	Director
3	Jainil R Bhatt	Chief Financial Officer (Key Managerial Personnel)
4	Hemant A Parikh	Director (Resigned wef 17.03.2026)
5	Rina Kumari	Independent Director
6	Hitesh Rijwani	Independent Director
7	Siddhi Shah	Company Secretary (Resigned wef 26.09.2025)
8	Parth Hemant Parikh	Promoter of the Company and also provides an unsecured loan to Vivanta Industries Limited
9	Parth Hemant Parikh	Promoter of the Company and also provides an unsecured loan to Vivanza Biosciences Limited
10	Ravina Aditya Parikh	Promoter of the Company
11	Ravina Aditya Parikh	Promoter of the Company and also provides an unsecured loan to Vivanza Biosciences Limited
12	Tarla Amrishbhai Parikh	Promoter of the Company
13	Tarla Amrishbhai Parikh	Promoter of the Company and also provides an unsecured loan to Vivanza Biosciences Limited
14	Vivanza Lifesciences Private Limited	Wholly Owned Subsidiary
15	Vivanza Lifesciences Private Limited	Mr. Hemant A. Parikh is a Director of the Company has provides an unsecured loan to Vivanza Lifesciences Private limited
16	Viva Energy Fertilizers Private Limited	Mr. Hemant A Parikh Director of the Company is Director in Viva Energy Fertilizers Private Limited
17	Viva Energy Fertilizers Private Limited	Mr. Hemant A Parikh Director of the Company has given an unsecured loan to this company.
18	Vitaaglobal Bioscience Private Limited	Mr. Hemant A Parikh Director of the Company are Director in Vitaaglobal Bioscience Private Limited and also provides and unsecured loan to this company.

19	Vital I.P. Private Limited (Formerly known as Vital Interiors &Furnitures Private Limited) VITAL I.P. Private Limited	Mr. Hemant A Parikh Director of the Company are Director of vital I.P. Private limited (Formerly known as Vital Interiors &Furnitures Private Limited)
20	Vital I.P. Private Limited (Formerly known as Vital Interiors &Furnitures Private Limited) VITAL I.P. Private Limited	Mr. Hemant A Parikh Director of the Company has provided an unsecured loan to this Company
21	VipronovaLifescience Private Limited	Mr. Hemant A Parikh and Parth Hemat Parikh Director of the Company was a Director in VipronovaLifescience Private Limited
22	Vitale Beverages Private Limited	Mr. Hemant A Parikh Director of the Company has provides an unsecured loan to this Company
23	Vitale Beverages Private Limited	Mr. Hemant A Parikh Director of the Company are Director in Vitale Beverages Private Limited
24	CKIM Pharma LLP	Joint Venture LLP and Mr. Hemant Parikh is a Designated Partner in this LLP
25	Viva Surbhi Biotech LLP	Mr. Hemant A. Parikh is a Director in Viva Surbhi Biotech LLP
26	Vaishali Lifecare Private Limited	Mr. Hemant A. Parikh Director of the Company has given an unsecured loan to this Company.
27	Winfra Green Projects Private Limited	Mr. Hemant A. Parikh Director of the Company has given an unsecured loan to this Company.
28	Winfra Green Projects Private Limited	Mr. Parth Parikh Promoter of the Company has given an unsecured loan to this Company.
29	Meghdhanush Drones and Agro Technologies Private Limited	Mr. Parth Parikh Promoter of the Company has given an unsecured loan to this Company.
30	Winfra Green Projects Private Limited	Ms. Ravina Aditya Parikh Promoter of the Company has given an unsecured loan to this Company.
31	Winfra Green Projects Private Limited	Ms. Tarla Parikh Promoter of the Company has given an unsecured loan to this Company.
32	Vital Intelligence Technology Private Limited	Mr. Parth Parikh Promoter of the Company has given an unsecured loan to this Company.

- **Transactions with Related Parties**

  Transactions that have taken place during the period April 1, 2025 to March 31, 2026 withrelated parties by the company stated below:

Sr. No.	Name	Nature of the Transaction	Amount Outstanding
1	Vivanza Lifesciences Pvt. Ltd.	Loan Granted Loan Recovered **Closing Balance** Purchase Sales	1.21 19.92 **NIL** 260.85 110.34

2	Jainil Bhatt	Directors Remuneration Payable Directors Remuneration Paid	3.30 3.65
		Closing Balance	**NIL**
		Loan Granted	0.00
		Loan Recovered	0.33
		Closing Balance	**0.80**
3	Rina Kumari	Opening Balance Salary Payable Paid Closing Balance	0.00 0.52 0.52 0.00
4	Hitesh Rijwani	Opening Balance Salary Payable Paid Closing Balance	0.00 0.40 0.40 0.00
5	Siddhi Shah	Opening Balance Salary Payable Paid Closing Balance	0.44 4.51 4.95 0.00
6	Parth Hemant Parikh	Opening Balance Loan Given Loan Repayment Closing Balance	20.00 0.00 0.00 20.00
7	Ravina Aditya Parikh	Opening Balance Loan Given Loan Repayment Closing Balance	20.00 0.00 0.00 20.00
8	Tarla Amrish Parikh	Opening Balance Loan Given Loan Repayment Closing Balance	20.00 0.00 0.00 20.00
9	Vitaaglobal Bioscience Private Limited	Sales Purchase Loan Granted Loan Recovered **Closing Balance**	NIL NIL NIL NIL **102.90**
10	Winfra Green Projects Private Limited	Loan Taken Loan Paid **Closing Balance**	267.47 87.22 **524.60**
11	Viva Surbhi Biotech LLP	Opening Balance Loan Given Loan Repayment Closing Balance	2.00 0.00 0.00 2.00
12	Vaishali Lifecare Private Limited	Opening Balance Loan Given Loan Repayment Closing Balance	6.39 0.00 0.00 6.39

- **Other Disclosures**

  The figures of the corresponding previous periods have been regrouped/ reclassified, wherever necessary to conform to the current period'spresentation.

- **Payment to the Auditors**

Particulars	2025-26	2024-25
Audit Fees	0.50	0
Company Matter	0.00	0
Income Tax Fees	0.00	0
Others	0.00	0
Total	**0.50**	**00**

- **Earnings per Share:-**

  The earning considered in ascertaining the company's EPS comprises the profit available for shareholders i.e. profit after tax and statutory/regulatory appropriations. The number of shares used in computing Basic EPS is the weighted average number of shares outstanding during the year as per the guidelines of IndAS-33.

Particulars	31-03-2026	31-03-2025
Net Profit Attributable to share holders	37.50	(69.51)
Weighted average number of equity shares (Nos.)	400.00	400
Basic and diluted earnings per share (Rs.)	0.09	(0.17)
Nominal value of equity share (Rs.)	1	1

- **Details of loan made during the year 2025-26 as per section 186(4) of The Companies Act 2013**

  The particulars of loans given, investments made, guarantees given and securities provided along with the purpose for which the loan or guarantee or security is proposed to be utilised as per the provisions of Section 186 of the Act are provided in the standalone financial statements. (Please refer to Notes to the standalone financial statements).

- **Capital Management**

  The Company manages its capital to ensure that entities in the Company will be able to continue as going concerns whilemaximizing the return to stakeholders through the optimization of the debt and equity balance. The capital structure of theCompany consists of net debt (borrowings offset by cash and bank balances) and total equity of the Company.

(Rs In Lakhs)

Particulars	As at 31st March,2026	As at 31st March,2025
- Total equity attributable to the		
equity shareholders of the company	400.00	400.00
- As percentage of total capital	34.84%	55.77%
- Current loans and borrowings	662.18	531.73
- Non-current loans and borrowings	87.72	77.53
- **Total loans and borrowings**	**749.90**	**609.26**
- Cash and cash equivalents	1.78	4.94
- Net loans & borrowings	748.12	604.32
- As a percentage of total capital	65.16%	60.17%
Total capital (loans and borrowings and equity)	**1148.12**	**717.23**

➢ **Fair Value measurements**

A. Financial instruments by category

(In Lakhs)

Particulars	As at 31st March, 2026			As at 31st March, 2025		
	Amortized Cost	FVTPL	FVTOCI	Amortized Cost	FVTPL	FVTOCI
Financial Asset						
Investment	-	191.45	-	-	191.45	-
Other Non-Current Asset	-	59.33	-	-	59.33	-
Trade receivables	-	1,066.01	-	-	738.59	-
Cash & Cash Equivalents	-	1.78	-	-	4.94	-
Loan	-	162.60	-	-	180.49	-
Total Financial Asset	**-**	**1481.17**	**-**	**-**	**1157.34**	**-**
Financial Liabilities						
Borrowings	-	749.92	-	-	609.26	-
Trade Payables	-	606.87	-	-	321.8	-
Other Financial Liabilities	-	-	-	-	-	-
Total Financial Liabilities	**-**	**1356.79**	**-**	**-**	**931.06**	**-**

* Excluding investments in subsidiaries, joint control entities and associates measured at cost in accordance with Ind AS-27

Fair value hierarchy

The following section explains the judgments and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value through profit or loss. To provide an indication about the reliability of the inputs used in determining fair value, the Company has classified its financial investments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

B. Fair value hierarchy for assets

Financial assets measured at fair value at March 31, 2026

	Level 1	Level 2	Level 3	Total
Financial Assets				
Investment	-	191.45	-	191.45

Financial assets measured at fair value at March 31, 2025

	Level 1	Level 2	Level 3	Total
Financial Assets				
Investment	-	191.45	-	191.45

Notes:

Level 1 hierarchy includes financial instruments measured using quoted prices (unadjusted) in active market foridentical assets that the entity can access at the measurement date. This represents mutual funds that have pricequoted by the respective mutual fund houses and are valued using the closing Net asset value (NAV).

Level 2 hierarchy includes the fair value of financial instruments measured using quoted prices for identical or similarassets in markets that are not active.

Level 3 if one or more of the significant inputs is not based on observable market data, the instrument is included inlevel 3. This is the case for unlisted compound instruments.

There are no transfers between any of these levels during the year. The Company's policy is to recognize transfersinto and transfers out of fair value hierarchy levels as at the end of the reporting period.

C. Fair value of financial assets and liabilities measured at amortized cost

The Management has assessed that fair value of loans, trade receivables, cash and cash equivalents, other bankbalances, other financial assets and trade payables approximate their carrying amounts largely due to their short termnature. Difference between carrying amount of Bank deposits, other financial assets, borrowings and otherfinancial liabilities subsequently measured at amortized cost is not significant in each of the years presented.

For financial assets and liabilities that are measured at fair value, the carrying amounts are equal to the fair values.

- **Financial risk management**

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The board has established the Audit Committee, which is responsible for developing and monitoring the Company's risk management policies. The Committee holds regular meetings and report to board on itsactivities. The Company's risk management policies are established to identify and analyses the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through itstraining and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.The audit committee oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

This note explains the sources of risk which the entity is exposed to and how the entity manages the risk.

Risk	Exposure arising from	Measurement	Management of risk
Credit Risk	Cash and cash equivalents, trade receivables, Financial assets measured at amortized cost.	Aging analysis	Diversification of funds to bank deposits, Liquid funds and Regular monitoring of credit limits
Liquidity Risk	Borrowings and other liabilities	Rolling cash flow forecasts	Availability of surplus cash, committed credit lines and borrowing facilities
Market Risk	Recognized financial assets andliabilities not denominated inIndian rupee	Cash flow forecasting sensitivity analysis	Regular monitoring to keep thenet exposure at an acceptablelevel.
Price Risk	Investments in mutual funds	Credit ratings	Portfolio diversification and regular monitoring

(a) Credit risk

Credit risk is the risk of financial loss to the company if a customer or counterparty to a financial instrument fails tomeet its contractual obligations. The company is exposed to the credit risk from its trade receivables, unbilledrevenue, investments, cash and cash equivalents, bank deposits and other financial assets. The maximum exposureto credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk isto prevent losses in financial assets.

Trade Receivables

Trade receivables comprise a widespread customer base. Management evaluates credit risk relating to customers on an on-going basis. If customers are independently rated, these ratings are used. Otherwise, if there is no independent rating, risk control assesses the credit quality of the customer, taking into account its financial position, past experience and other factors

For trade receivables, provision is provided by the company as per the below mentioned policy:

Particulars	Gross Carrying Amount	Expected credit losses rate (%)	Expected Credit Losses	Carrying amount of Trade Receivable
Considered for Goods				
0-6 Months	515.19	0	0	515.19
More than 6 Months	550.82	0	0	550.82
Total	**1,066.01**	**0**	**0**	**1,066.01**

(b) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with itsfinancial liabilities that are settled by delivering cash or another financial asset. The Company's approach tomanaging liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they aredue, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to theCompany's reputation.

Liquidity Table

The Company's remaining contractual maturity for its non-derivative financial liabilities with agreed repaymentperiods is given below. The tables have been drawn up based on the undiscounted cash flows of financial liabilitiesbased on the earliest date on which the Company can be required to pay. The tables include both interest andprincipal cash flows. The contractual maturity is based on the earliest date on which the Company may be requiredto pay.

As at March 31, 2026

(In Lakhs)

Financial Liabilities	Payable within 0 to 12 months	More than 12 months	Total
Non-current financial liabilities			
Borrowings	-	87.72	87.72
Current financial liabilities			
Borrowings	662.18	-	662.18
Trade Payables	579.32	27.55	606.87
Other Financial Liability		-	-
Total financial liabilities	**1241.5**	**115.27**	**1356.77**

As at March 31, 2025

Financial Liabilities	Payable within 0 to 12 months	More than 12 months	Total
Non-current financial liabilities			
Borrowings	-	77.52	77.52
Current financial liabilities			
Borrowings	531.73	-	531.73
Trade Payables	90.34	231.46	321.8
Other Financial Liability			-
Total financial liabilities	**622.07**	**308.98**	**931.05**

(c) Market Risk

Market risk is the risk arising from changes in market prices – such as foreign exchange rates and interest rates – willaffect the Company's income or the value of its holdings of financial instruments. The Company is exposed to market risk primarily related to interest rate risk and themarket value of the investments. Thus, the exposure to market risk is a function of investing and borrowing activities

- **Interest rate risk**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

Most of the Company's borrowings are on a floating rate of interest. The Company has exposure to interestrate risk, arising principally on changes in Marginal Cost of Funds based Lending Rate (MCLR). The Companyuses a mix of interest rate sensitive financial instruments to manage the liquidity and fund requirements for itsday to day operations like short term credit lines besides internal accruals.

The exposures of the Company's financial assets / liabilities at the end of the reporting period are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Floating Rate Borrowings	136.62	187.38

(d) Price Risk

Exposure

The Company's exposure to securities price risk arises from investments held in mutual funds and classified inthe balance sheet at fair value through profit or loss. To manage its price risk arising from such investments, theCompany diversifies its portfolio. Further these are all debt base securities for which the exposure is primarilyon account of interest rate risk. Quotes (NAV) of these investments are available from the mutual fund houses.Profit for the year would increase/decrease as a result of gains/losses on these securities classified as at fairvalue through profit or loss.

➢ **<u>Others</u>**

- Balance Sheet is still carrying Opening Balance of "P & P Expenses and issue related expensesofRs. 3.66/-(In Lakhs) as "Other Current Assets", which in our opinion needs to be writtenoff in Two Financial Years proportionately. And Due to the same expense isunder stated in profit & loss account.
- Balance of sundry debtors and creditors, loans and advances accepted and given in the balance sheet are subject to confirmation.
- As informed by the management that the loans are interest free, which in our opinion is violation of Section 186 (7) of the Companies Act, 2013.
- Above Disclosure is made after taking into account the principle of materiality.
- In the events of non-availability of suitable supporting vouchers, Directors have given us certificate that these expenses are incurred mainly for the business activities of the company.

- The previous year's figures have been reworked, regrouped, rearranged and reclassified wherever necessary. Amounts and other disclosures for the preceding year are included as an integral part of the current year financial statements and are to be read in relation to the amounts and other disclosures relating to the current year.
-

Financial Ratios for the Financial Year 2025-26:

(In Lakhs)

Sr.	Financial Ratios	Particulars	Numerator / Denominator taken	As at 31st March, 2026	As at 31st March, 2025	% change in Ratio	Remark - Any change in the ratio by more than 25% as compared to the preceding year.
1	**Current Ratio (CA/CL)**	**Ratio**		**1.20**	**1.25**	**(4.45)**	Within the Limit
		Numerator	Current Assets	1,559.47	1,138.31		
		Denominator	Current Liabilities	1,295.28	911.65		
2	**Debt-Equity Ratio**	**Ratio**		**1.71**	**1.52**	**12.24**	Within The Limit
		Numerator	Total Borrowings (Including Current Maturities of Long term borrowing)	749.90	609.26		
		Denominator	Total Equity	439.54	402.04		
3	**Debt Service Coverage Ratio**	**Ratio**		**2.85**	**(0.98)**	**(391.31)**	1.Due to Profit in Current year.
		Numerator	Profit before exceptional items, taxes, Depreciation and Amortisation Expenses and Interest Expenses	79.71	(32.89)		
		Denominator	1. Interest on Loan 2. Current Maturities of Long-term loan (Instalments)	27.92	35.08		
4	**Return on Equity Ratio**	**Ratio**		**8.53**	**(17.29)**	**(149.34)**	1.Due to Profit in Current year.
		Numerator	Profit for the year after tax	37.50	(69.51)		
		Denominator	Average Total Equity	439.54	402.04		

5	**Inventory Turnover Ratio**	**Ratio**		**46.36**	**1.44**	**3119.18**	1.Due to increase in cogs.
		Numerator	Cost of Goods Sold	11,096.83	262.48		
		Denominator	Average Inventories	239.38	182.11		
6	**Trade Receivables Turnover Ratio**	**Ratio**		**12.44**	**0.40**	**3009.57**	1.Due to Increase in revenue from operations.
		Numerator	Revenue from Operations	11,223.10	294.28		
		Denominator	Average Trade receivables	902.30	738.59		
7	**Trade Payables Turnover Ratio**	**Ratio**		**24.14**	**0.83**	**2807.92**	1.Due to increase in purchases.
		Numerator	Total Purchases	11,207.08	266.77		
		Denominator	Average Trade payables (including advance from customer)	464.34	321.80		
8	**Net Capital Turnover Ratio**	**Ratio**		**42.48**	**1.30**	**3167.81**	1. Due to Increase in revenue from operations
		Numerator	Revenue from Customers	11,223.10	294.28		
		Denominator	Average Working Capital	264.19	226.65		
9	**Net Profit Ratio (PAT/Revenue)**	**Ratio**		**0.33**	**(23.62)**	**(101.41)**	1.Due to Profit in current year.
		Numerator	Profit after Taxes	37.50	(69.51)		
		Denominator	Revenue from Customers	11,223.10	294.28		

10	**Return on Capital employed**	**Ratio**		**9.82**	**(14.46)**	**(167.92)**	1.Due to Profit in current year.
		Numerator	Profit before tax and Interest expense	51.79	(69.36)		
		Denominator	Capital Employed	527.26	479.56		
11	**Return on Investment**	**Ratio**		**0.00**	**0.00**	**0.00**	Within the Limit
		Numerator	Income From Investment	-	-	-	
		Denominator	Cost of Investment	191.45	191.45	-	

For, Vivanza Biosciences Limited

For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

Jayendra Mehta
Managing Director
DIN:08210602

Sarang Pathak
Director
DIN: 02663344

Jainil Bhatt
CFO

CA Shivam Soni
Proprietor
Memberships No. 178351
UDIN:26178351EMKFBH6295

Place: Ahmedabad
Date:07TH May, 2026

Independent Auditor's Report

To
The Members of
Vivanza Biosciences Limited

Opinion

We have audited the consolidated financial statements of Vivanza Biosciences Limited (hereinafter referred to as the "Holding Company" or the "Corporation") and its subsidiaries (Holding Company and its subsidiaries together referred to as the "Group") and its associates, which comprise the consolidated balance sheet as at 31 March 2026, and the consolidated statement of profit and loss (including other comprehensive income), consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as the "consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate financial statements of such subsidiaries and associates as were audited by the other auditors, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group and its associates as at 31 March 2026, of its consolidated profit and other comprehensive income, consolidated changes in equity and consolidated cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group, its associate and joint ventures in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in terms of the Code of Ethics issued by the Institute of Chartered Accountants of India and the relevant provisions of the Act, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Emphasis of matter

- We draw the attention regarding non charging of Interest on Loans & Advances to Related Parties and other parties' u/s. 186 of the Companies Act, 2013.

- The company has in past granted/ renewed loans and advances to other companies, which has been identified as non – performing asset. Accordingly, company has not recognized any income from the same. In the opinion of the directors, the process of recovery is going on and the same is not fully doubtful of recovery.
  Our opinion is not qualified in respect of this matter.

Management's and Board of Directors' Responsibilities for the Consolidated Financial Statements

The Holding Company's management and Board of Directors are responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Act that give a true and fair view of the consolidated state of affairs, consolidated profit/ loss and other comprehensive income, consolidated statement of changes in equity and consolidated cash flows of the Group including its associate and joint ventures in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. The respective

Management and Board of Directors of the companies included in the Group and of its associate and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of each company and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Management and Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Management and Board of Directors of the companies included in the Group and of its associate and joint ventures are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate and joint ventures is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements
Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on the internal financial controls with reference to the consolidated financial statements and the operating effectiveness of such controls based on our audit.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors
- Conclude on the appropriateness of Management and Board of Directors use of the going concern basis of accounting in preparation of consolidated financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate and joint ventures to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of such entities or business activities within the Group and its associate and joint ventures and joint operations to express an opinion on the consolidated financial statements, of which we are the independent auditors. We are responsible for the direction, supervision and performance of the audit of financial information of such entities. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143 (11) of the Act, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by section 143(3) of the Act, we report that:
   a) We have sought and obtained all the information and an explanation which is to the best of our knowledge and beliefs were necessary for the purposes of our audit.
   b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.
   c) The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
   d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standard) Rules, 2015, as amended
   e) On the basis of written representations received from the directors as on 31st March, 2026, taken on record by the Board of Directors, none of the directors is disqualified as on 31st March2026, from being appointed as a director in terms of Section 164(2) of the Act.
   f) With respect to the other matters included in the Auditor's Report and to our best of our information and according to the explanations given to us:
      i. The Company does not have any pending litigations which would impact its financial position.

ii. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.

3. In accordance with the Ministry of Corporate Affairs (MCA) mandate effective from 1 April 2023, companies are required to maintain an audit trail for transactions affecting books of accounts. It is noted that Vivanza Bioscience Limited has not implemented this audit trail reporting feature. This information is disclosed for transparency in our audit report.

There is no amount required to be transferred, to the investor's education & Protection Fund by the Company.

For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

CA Shivam Soni
Proprietor
Membership No: 178351
UDIN: 26178351OXOEJD2109

Place: Ahmedabad
Date: 7th May, 2026

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **M/S VIVANZA BIOSCIENCES LIMITED** (“the Company”) as of March 31, 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding company, its subsidiary companies, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on, “internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI)”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company and its subsidiary companies, which are companies incorporated in India, have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

S.D/-
CA Shivam Soni
Proprietor
Membership No: 178351
UDIN: 26178351OXOEJD2109

Place: Ahmedabad
Date: 7th May, 2026

VIVANZA BIOSCIENCES LIMITED
(CIN:L24110GJ1982PLC005057)
CONSOLIDATED BALANCE SHEET AS AT 31/03/2026

(Rs. in Lakhs)

Particulars	Note No.	As at 31st March, 2026	As at 31st March, 2025
I. ASSETS			
1 Non Current Asset			
(a) Property, Plant and Equipment	1	80.13	69.89
(b) Capital Work-In-Progress		-	-
(c) Other Intangible Asset	1	3.00	3.00
(d) Goodwill	1	160.54	160.54
(e) Financial Asset			
(i) Investments	2	0.25	0.25
(ii) Other Non current Financial Assets	3	59.33	59.33
(iii) Loan	4	-	113.82
(f) Deferred Tax Assets(Net)		-	0.06
Total Non-Current Assets		303.26	406.89
2. Current Assets			
(a) Inventories	5	355.07	226.31
(b) Financial Assets			
(i) Trade Receivables	6	1,238.33	805.93
(ii) Cash And Cash Equivalent	7	6.53	11.69
(iii) Loan	8	270.99	164.36
(c) Other Current Asset	9	34.56	30.15
Total Cuurent Assets		1,905.49	1,238.43
Total Assets		2,208.74	1,645.32
II. Equity & liabilities			
1. Equity			
(a) Equity Share Capital	10	400.00	400.00
(b) Other Equity	11	35.85	(3.59)
Total Equity		435.85	396.41
2. Liabilities			
(a) Non Current Liabilities			
(i) Borrowings	12	87.72	333.48
(ii) Dederred Tax Liabilities		0.02	-
(iii) Other Non-Current Liabilities		-	-
(b) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	13	931.46	531.73
(ii) Trade Payables	14	719.41	261.81
(iii) Other Financial Liabilities		-	-
(b) Other Current Liabilities	15	10.96	115.97
(C) Provisions	16	23.33	5.91
Total Liabilities		1,772.90	1,248.91
Total		2,208.74	1,645.32

Contingent Liabilities & Commitments Nil

For, Vivanza Biosciences Limited

For, SHIVAM SONI & Co.
Chartered Accountants
FRN : 152477W

Jayendra Mehta
Managing Director
DIN : 08210602

Sarang Pathak
Director
DIN : 02663344

Jainil Bhatt
CFO

CA Shivam Soni
Proprietor
Membership No. 178351
UDIN: 26178351OXOEJD2109

Place : Ahmedabad
Date : 07/05/2026

VIVANZA BIOSCIENCES LIMITED
(CIN:L24110GJ1982PLC005057)
CONSOLIDATED STATEMENT OF PROFIT & LOSS ACCOUNT FOR THE PERIOD FROM 01-04-2025 TO 31-03-2026

(Rs. in Lakhs)

	Particulars	Note No.	2025-26	2024-25
I	Revenue From Operations	17	11,591.06	742.33
II	Other Income	18	11.15	6.15
III	Total Income (I+II)		11,602.21	748.48
IV	Expenses			
	Purchase of Stock in Trade	19	11,571.38	707.74
	Changes in Inventories	20	(128.77)	(25.68)
	Employee Benefit Expenses	21	49.24	57.51
	Finance Costs	22	27.92	35.14
	Depreciation & Amortisation Expenses		2.16	1.40
	Other Expenses	23	25.91	38.94
	Total Expenses		11,547.84	815.05
V	Profit Before Exceptional & Extraordinary Items & Tax (III-IV)		54.37	(66.57)
VII	Exceptional Items		-	-
VIII	Profit Before Extraordinary Items & Tax		54.37	(66.57)
	Extraordinary Items		-	-
IX	Profit Before Tax		54.37	(66.57)
X	Tax Expenses			
	Current Tax		14.85	0.70
	Current Tax/ Interest on Income Tax/ Deferred Tax		0.09	0.14
XI	Profit/(Loss) for the period from Continuing Operations(IX-X)		39.44	(67.41)
XII	Profit/(Loss) from Discontinuing Operations			
XIII	Tax Expense of Discontinuing Operations			
XIV	Profit/(Loss) from Discontinuing Operations (after tax)(XII-XIII)		-	-
XV	Profit/(Loss) for the Period(XI+XIV)		39.44	(67.41)
	Other Comprehensive Income			
	Items that will not be reclassified to profit or loss		-	-
	Total comprehensive income for the year, net of tax		39.44	(67.41)
XVI	Earning Per Equity Share			
	Basic		0.10	(0.17)
	Diluted		0.10	(0.17)
The Notes referred to above form an integral part of the Balance Sheet				

For, Vivanza Biosciences Limited

Jayendra Mehta
Managing Director
DIN : 08210602

Sarang Pathak
Director
DIN : 02663344

Jainil Bhatt
CFO

Place : Ahmedabad
Date : 07/05/2026

For, SHIVAM SONI & Co.
Chartered Accountants
FRN : 152477W

CA Shivam Soni
Proprietor
Membership No. 178351
UDIN: 26178351OXOEJD2109

VIVANZA BIOSCIENCES LIMITED

(CIN:L24110GJ1982PLC005057)

Consolidated Cashflow Statement for the year ended on 31st March, 2026

Particulars	2025-26	2024-25
A Cash flow from Operating Activities		
Net Profit Before Tax	54.37	(66.57)
Adjustments for:		
Add Depreciation	2.16	1.40
Less Dividend Income	-	-
Less Diffrence due to consolidation	-	-
Add Interest Expenses	27.92	35.14
Operating Profit / (Loss) before Working Capital Changes	84.45	(30.03)
Adjustments for:		
Increase/(Decrease) in Trade Payables	457.60	(561.66)
Increase/(Decrease) in other current liabilities	(105.01)	(1.31)
Increase/(Decrease) in provisions	17.41	(22.70)
(Increase)/Decrease in short term loans & advances	113.82	(31.58)
Increase/(Decrease) in Borrowing	(245.76)	65.29
(Increase)/Decrease in Trade Receivables	(432.41)	348.01
(Increase)/Decrease in inventories	(128.77)	(25.68)
(Increase)/Decrease in other current assets	(4.41)	10.46
Cashflow generated from Operating Activities	(243.08)	(249.20)
Income Tax Paid (Net of Refund)	14.85	0.70
Net Cashflow generated from Operating Activities A	(257.93)	(249.90)
B Cash flow from Investment Activities		
Purchase of Property, Plant and Equipment	(12.40)	(0.79)
Sale of Investments	-	-
Purchase of Investments	-	-
Shares Issued	-	-
Dividend Income	-	-
Net Cashflow generated from Investments Activities B	(12.40)	(0.79)
C Cash flow from Financiang Activities		
Interest Expenses	(27.92)	(35.14)
(Increase)/Decrease in other non-current assets	-	-
(Increase)/Decrease in short term loans & advances	(106.63)	(2.14)
Increase/(Decrease) in non current liabilities & provisions	-	-
Increase /(Decrease) in Borrowings (Liabilities)	399.72	282.98
Increase/(Decrease) in other financial liabilities		
Net Change in Unsecured Loans Taken	-	-
Movement in Loans & Advances Granted	-	-
Net Cashflow generated from Financing Activities C	265.17	245.70
Net Change in Cash & Cash Equivalents (A+B+C)	(5.16)	(5.00)
Opening Cash & Cash Equivalents	11.69	16.69
Closing Cash & Cash Equivalents	6.53	11.69

Notes

1 Previous year's figures have been regrouped wherever necessary, to conform to this year's classification.

For, Vivanza Biosciences Limited

Jayendra Mehta
Managing Director
DIN : 08210602

Sarang Pathak
Director
DIN : 02663344

Jainil Bhatt
CFO

Place : Ahmedabad
Date : 07/05/2026

For, SHIVAM SONI & Co.
Chartered Accountants
FRN : 152477W

CA Shivam Soni
Proprietor
Membership No. 178351
UDIN: 26178351OXOEJD2109

VIVANZA BIOSCIENCES LIMITED

(CIN:L24110GJ1982PLC005057)

Consolidated Statement of changes in equity for the period ended March 31, 2026

Amount in Rs. (Rs. in Lakhs)

A. Equity Share Capital		
Particulars	No. Shares	Amount
Changes in equity share capital during the year	-	-
Balance as at April 1, 2023	40,00,000.00	400.00
Changes in equity share capital during the year due to Splitting share of Rs.10 into Rs.1	3,60,00,000.00	360.00
Balance as at April 1, 2024	4,00,00,000.00	400.00
Equity share capital of face value Rs. 1/- each	4,00,00,000.00	400.00
Balance as at March 31, 2025	4,00,00,000.00	400.00
Equity share capital of face value Rs. 1/- each	4,00,00,000.00	400.00
Balance as at March 31, 2026	4,00,00,000.00	400.00

B. Other Equity (Rs. in Lakhs)

Particulars	Reserves and Surplus	Total
	Retained Earnings	
Balance as at 1st April, 2024	63.82	63.82
Profit / (Loss) for the year	(67.41)	(67.41)
Balance as at March 31, 2025	(3.59)	(3.59)
Profit / (Loss) for the year	39.44	39.44
Other comprehensive income	-	-
Total Comprehensive Income / (loss) for the year	39.44	39.44
Balance as at March 31, 2026	35.84	35.84

See accompanying notes to the financial statements

In terms of our report attached

For, Vivanza Biosciences Limited

Jayendra Mehta
Managing Director
DIN : 08210602

Sarang Pathak
Director
DIN : 02663344

Jainil Bhatt
CFO

Place : Ahmedabad
Date : 07/05/2026

For, SHIVAM SONI & Co.
Chartered Accountants
FRN : 152477W

CA Shivam Soni
Proprietor
Membership No. 178351
UDIN: 26178351OXOEJD2109

1. Property Plant & Equipment

(i) Tangible Fixed Assets

(Rs. in Lakhs)

Particulars	Gross Block					Depriciation					Net Block	
	Balance as at 01/04/2025	Addition	Deduction	Acquire through Business Combination	Balance as at 31/03/2026	Balance as at 01/04/2025	Depreciation Charge	Written Off	Deduction	Closing Balance	As at 31/03/2026	As at 31/03/2025
Land	14.18	-	-	-	14.18	-	-	-	-	-	14.18	14.18
Building	24.57	-	-	-	24.57	5.66	-	-	-	5.66	18.90	18.90
Borewell	0.56	-	-	-	0.56	0.22	-	-	-	0.22	0.33	0.33
Machinery	43.91	-	-	-	43.91	11.30	0.09	-	-	11.39	32.52	32.61
Furniture & Fixtures	2.20	-	-	-	2.20	1.20	-	-	-	1.20	1.00	1.00
Electrification	0.95	-	-	-	0.95	0.72	0.25	-	-	0.97	(0.02)	0.23
Laptop	2.50	-	-	-	2.50	2.20	0.02	-	-	2.22	0.28	0.30
Computer	0.28	-	-	-	0.28	0.07				0.07	0.21	0.21
Mobile	0.41	-	-	-	0.41	0.07	0.02			0.09	0.32	0.34
Car	-	12.40			12.40	-	1.03			1.03	11.37	-
Projector	3.47	-	-	-	3.47	1.68	0.75			2.43	1.04	1.79
Total Tangible Assets	93.02	12.40	-	-	105.42	23.13	2.16	-	-	25.29	80.13	69.89

(ii) Goodwill

Particulars	Gross Block				Depreciation	2025-26
	Opening	Addition	Deduction	Closing		Closing
Goodwill on consolidation	160.54	-	-	160.54	-	160.54
Total						160.54

(iii) Intangible Assets

Particulars	Gross Block				Depreciation	2025-26
	Opening	Addition	Deduction	Closing		Closing
Technical Know-how	3.00	-	-	3.00	-	3.00
Total						3.00

Notes to the Financial Statements

2 Non-current Investments (Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Other Investments - Un Quoted	0.25	0.25
(1) Investment in Equity Shares		
Equity Shares of Rs. 10/- each of J.V.N.S. Bank Limited	0.25	0.25
Total	0.25	0.25
Market Value of the Quoted Shares		-
Market Value of the Un Quoted Shares	0.25	0.25

3 Other Non current Financial Assets (Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Recoverable in Cash or Kind	59.33	59.33
Balance with Government Authorities	0.00	0.00
Total	59.33	59.33

4 Loans (Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Loan to Corporate Bodies	-	-
Loan to Related Parties	-	-
Other Loans	-	113.82
Total	-	113.82

5 Inventory (Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Stock In Trade	355.07	226.31
Total	355.07	226.31

6 Trade Receivables (Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Outstanding for less than 6 months from the due date	515.19	119.84
Unsecured, considered good		
Outstanding for more than 6 months from the due date	723.14	686.08
Unsecured, considered good		
Total	1,238.33	805.93

6 Trade Receivables ageing schedule *

(Rs. in Lakhs)

Particulars	As at 31st March, Outstanding for					
	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 year	Total
Undisputed Trade Receivable- considered good	515.19	485.61	-	-	237.53	1,238.33
Undisputed Trade Receivable- considered doubtful						-
Disputed Trade Receivable- considered good						-
Disputed Trade Receivable- considered doubtful						-

(Rs. in Lakhs)

Particulars	As at 31st March, Outstanding for					
	Less than 6 months	6 months - 1 year	1-2 year	2-3 year	More than 3 year	Total
Undisputed Trade Receivable- considered good	119.84	152.89	262.46	109.07	161.66	805.93
Undisputed Trade Receivable- considered doubtful						-
Disputed Trade Receivable- considered good						-
Disputed Trade Receivable- considered doubtful						-

7 Cash & Cash Equivalents (Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Balances with Banks	0.40	0.12
In Current Account	0.40	0.12
In Fixed Deposits held as margin money		
Secured Loan		-
Cash on Hand	6.13	11.57
Total	6.53	11.69

8 Loans

(Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Other Loans & Advances		
Unsecured, Considered good		
Loan to Corporate Bodies	15.00	15.00
Loan to Related Parties	112.67	111.49
Other Loans	125.45	20.42
VAT Credit	-	-
TDS & TCS credit	-	0.07
GST Credit	17.57	17.18
VAT & CST Deposit	0.20	0.20
Advances to Staff	-	-
Other Deposit	0.10	-
Total	270.99	164.36

9 Other Current Assets

(Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Prelimnary & Preoperative Expenses	-	-
Public Issue Expenses	-	-
Balance With Government Authorities (TDS/TCS)	6.47	
Balance With Government Authorities (GST)	4.07	
Deposit	2.89	2.99
Advances to Trade Payble	21.13	27.16
Total	34.56	30.15

10 Equity Share Capital

10 Authorized, Issued, Subscribed and Paidup share capital (Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
	Amount	Amount
Authorised Share Capital		
4,00,00,000 Equity Shares of Rs.1 Each	4,00,00,000.00	400.00
Total	4,00,00,000.00	400.00
Issued Share Capital		
4,00,00,000 Equity Shares of Rs.1 Each	4,00,00,000.00	400.00
	4,00,00,000.00	400.00
Subscribed & Fully Paid		
4,00,00,000 Equity Shares of Rs.1 Each	4,00,00,000.00	400.00
Total	4,00,00,000.00	400.00

10 Details of the Shares for the Preceding Five Years

Particulars	01-04-2021 to 31-03-2026
Number Of Equity Shares Bought Back	-
Number Of Preference Shares Reedeemed	-
Number of Equity Share Issue as Bonus Share	-
Number of Preference Share Issue as Bonus Share	-
Number of Equity Shares Allotted For Contracts	-
Without Payment Received In Cash	-
Number of Preference Shares Allotted For Contracts	-
Without Payment Received In Cash	-

1.3 Reconciliation of Share Capital (Rs. in Lakhs)

Particulars	As at 31st March, 2026		As at 31st March, 2025	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares				
(Face Value Rs. 1)				
Shares Outstanding at the Beginning of the Year	4,00,00,000.00	400.00	4,00,00,000.00	400.00
Shares cancelled during the year (Under the Scheme of Capital Reduction)	-	-	-	-
Shares issued during the year (Under the Scheme of Capital Reduction)	-	-	-	-
Shares issued during the year (Against Shares of Subsidiary Company)	-	-	-	-
Shares Outstanding at the End of the Year	4,00,00,000.00	400.00	4,00,00,000.00	400.00

1.4 Share Holders Holding More than 5% Share (Rs. in Lakhs)

Name of the Share Holders	As at 31st March, 2026		As at 31st March, 2025	
	No. of Shares	% of Holding	No. of Shares	% of Holding
Parth Hemant Parikh	1,71,95,510.00	42.99	1,71,95,510.00	42.99
Hemant Parikh	1,00,211.00	0.25	1,00,211.00	0.25
Ashok Metcast Limited	15,39,259.00	3.85	77,49,088.00	19.37
Ardent Ventures LLP	92,37,000.00	23.09	92,37,000.00	23.09

1.5 Shares held by Promoters at the end of the year

Name of the Promoter	As at 31st March, 2026		As at 31st March, 2025		% Change during the year
	No. of Shares	% of total share	No. of Shares	% of total share	
PARTH HEMANT PARIKH	1,71,95,510.00	42.99	1,71,95,510.00	42.99	-
Hemant Parikh	1,00,211.00	0.25	1,00,211.00	0.25	-

11 Other Equity

(Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Profit & Loss A/c		
Opening balance	(3.59)	63.82
(+) Amount of Share Capital transferred on Capital Reduction Scheme		-
(+) Transfer of Current Year Profit	39.44	(67.41)
Closing balance	35.85	(3.59)
Total	35.85	(3.59)

12 Non Current Borrowings

(Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Secured Loans		
From Banks	10.19	
	-	
Unsecured Loans repayable on Demand	-	
Loan From Relatives of Directors & Other Companies	17.53	273.48
Other Borrowings	60.00	60.00
Total	87.72	333.48

13 Current Borrowings

(Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Unsecured Loans repayable on Demand		
Loan From Relatives of Directors & Other Companies	794.84	344.35
SBI CC A\C	136.62	187.38
Other Borrowing	-	-
Total	931.46	531.73

14 Trade Payables

(Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Unsecured Loans repayable on Demand		
Due to Micro & Small Enterprises	-	-
Others	719.41	261.81
Total	719.41	261.81

** The Company has not received any intimation on suppliers regarding their status under the Micro, Small and Medium Enterprise Development (MSMED) Act, 2006 and hence

(a) Amount due and outstanding to suppliers as at the end of the accounting year;

(b) interest paid during the year;

(c) interest payable at the end of the accounting year;

(d) interest accrued and unpaid at the end of the accounting year; have not been given , the company is making efforts to get the confirmation from the suppliers as regards their status under the

14 *Trade Payables ageing schedule (Rs. in Lakhs)

Particular	As at 31st March, 2026				
	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
MSME	-	-	-	-	-
Others**	691.85	3.32	23.90	0.33	719.41
Disputed dues MSME	-	-	-	-	-
Disputed dues Others	-	-	-	-	-
Total					719.41

*Trade Payables ageing schedule

(Rs. in Lakhs)

Particulars	As at 31st March, 2025				
	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
MSME	-	-	-	-	-
Others**	90.34	166.21	4.74	0.52	261.81
Disputed dues MSME	-	-	-	-	-
Disputed dues Others	-	-	-	-	-
Total					261.81

15 Other Current Liabilities
(Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
Statutory Dues	8.14	0.08
Other Payables	0.44	0.08
Advance from Trade receivable	2.38	54.16
Sundry Creditor of Vivanza Life sciences Pvt Ltd	-	-
Other current liablities	-	61.64
Total	10.96	115.97

16 Provisions
(Rs. in Lakhs)

Particulars	As at 31st March, 2026	As at 31st March, 2025
TDS On contractor	-	-
Unpaid Audit Fees	-	1.05
Others	-	-
Income Tax Provision	15.60	2.31
Salary payable	7.73	2.55
Leave encashment		
Total	23.33	5.91

17 Revenue from Operations
(Rs. in Lakhs)

Particulars	2025-26	2024-25
GST Taxable Supply	10,506.03	621.37
GST NIL Rates Supply	1,085.03	120.96
GST Zero Rated Supply		
Technical Dossier Fee		
Total	11,591.06	742.33

18 Other Income
(Rs. in Lakhs)

Particulars	2025-26	2024-25
Discount Income (Kasar)	0.62	-
Duty Drawbak	-	1.33
Interest Income	-	
Other Income	2.65	4.83
Asset & Liabilities Written off	7.67	
Freight	0.22	
	-	
Total	11.15	6.15

19 Purchase of Stock in Trade

(Rs. in Lakhs)

Particulars	2025-26	2024-25
GST Taxable Purchase	11,571.38	707.74
GST Exempt Purchase		-
Total	11,571.38	707.74

20 Change in Inventory

(Rs. in Lakhs)

Particulars	2025-26	2024-25
(A) Opening Stock	226.31	200.63
Finished Goods		
(1) Cattle Feed (Cemex)	24.96	24.96
(2) I V Fluid	-	-
(3) Pharma	82.98	57.30
(4) Real Cow Ghee	-	-
(B) Opening Stock of Branch Delhi	118.37	118.37
(A) Closing Stock	355.07	226.31
Finished Goods		
(1) Cattle Feed (Cemex)	24.96	24.96
(2) I V Fluid	-	
(3) Pharma	211.75	82.98
(4) Real Cow Ghee	-	
(B) Closing Stock of Branch Delhi	118.37	118.37
Total	(128.77)	(25.68)

21 Employee Benefit Expenses

(Rs. in Lakhs)

Particulars	2025-26	2024-25
Directors Remuneration	-	-
Salary & Wages	49.24	57.51
Total	49.24	57.51

22 Finance Costs

(Rs. in Lakhs)

Particulars	2025-26	2024-25
Interest Expense	27.92	35.14
Total	27.92	35.14

23 Other Expenes (Rs. in Lakhs)

Particulars	2025-26	2024-25
Payment to Auditors *	0.80	0.55
Advertisement Expenses	0.63	0.39
Share Listing & Processing Fees	1.75	3.82
Office Expenses	0.21	3.26
Bank Charges	0.41	0.28
Bonus	-	
Business Pramotion Exp.	-	0.10
E Voting Charges	-	0.06
Import-Export Charges	2.77	0.50
Printing & Stationary Expenses	0.99	0.59
Legal & Professional Charges	3.86	3.27
Processing fees	-	0.38
ROC Fees	-	
Rent Expenses	-	1.77
Registration fees	-	0.08
Insurance Expenses	0.24	0.23
Transportation Expenses	0.61	0.92
Analytical Expenses	-	
Freight Expenses	7.53	11.53
Postage & Courier	0.01	0.46
Packing Material Charges	-	0.05
Product approval expenses	-	
Travelling Expenses	2.17	1.10
Preliminary expenses W/off	-	3.68
Software Licence Fees	0.03	0.03
Share Certifiacte Expense	-	0.18
Share Registrar Fees	0.84	
Other Miscellaneous Expenses	2.02	2.16
Foreign Exchange Loss	0.49	0.91
Inspection And Testing Charges	0.51	
Discount	-	2.52
Conveyance Expenses	0.04	0.12
Total	25.91	38.92
* Payment to Auditors		
For Audit Fees	0.80	0.55
For Others	-	-

23. Significant Accounting Policies

- **Company Overview**
  Vivanza Biosciences Limited("the company") is a listed company domiciled in India and incorporated under the provisions of the Companies Act, 1956. The company is engaged in the business of Pharmaceutical Products, Pharma Products. The company is listed on Bombay Stock Exchange.

- **Basis of preparation and presentation**

  i. **Basis of Preparation**
  The Consolidated Financial Statements of the Group have been prepared to comply with the Indian Accounting Standards ('Ind AS'), including the rules notified under the relevant provisions of the Companies Act, 2013.The Consolidated Financial Statements comprises of Vivanza Biosciences Limited and its subsidiaries, being the entities that it controls. Controls are assessed in accordance with the requirement of Ind AS 110 - Consolidated Financial Statements.

  ii. **Basis of Measurement**
  The financial statements have been prepared on a historical cost basis, except for the following:

    - certain financial assets and liabilities (including derivative instruments) that are measured at fair value (refer accounting policy regarding financial instruments)
    - asset held for sale and biological Assets – measured at fair value less cost to sell;
    - defined benefit plans – plan assets measured at fair value less present value of defined benefit obligation; and
    - share-based payments

- **Basis of Consolidation**
  a) The financial statements of the Holding Company and its subsidiaries are combined on a line by line basis by adding together like items of assets, liabilities, equity, incomes, expenses and cash flows, after fully eliminating intra-group balances and intra-group transactions.
  b) Profits or losses resulting from intra-group transactions that are recognized in assets, such as Inventory and Property, Plant and Equipment, are eliminated in full.
  c) Goodwill represents the difference between the Company's share in the net worth of subsidiaries and the cost of acquisition at each point of time of making the investment in the subsidiaries.
  d) The Consolidated Financial Statements have been prepared using uniform accounting policies for like transactions and other events in similar circumstances.
  e) The Financial statements of the current financial year are consolidated financial statements, whereas the comparative information is standalone financial statement of preceding financial year.

- **Functional and Presentation Currency :**
  Items included in the financial statements of the company are measured using the currency of the primary economic environment in which the company operates ("the functional currency"). Indian Rupee is the functional currency of the company.

The financial Statements are presented in Indian Rupees and all values are rounded to the nearest lakhs as per the requirement of Schedule III, except when otherwise indicated.

- **Current versus non-current classification**

  The Company presents assets and liabilities in the balance sheet based on current/ non-current classification an asset is classified as current when it satisfies any of the following criteria:

- It is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle. it is held primarily for the purpose of being traded;
- it is expected to be realized within 12 months after the reporting date; or
- It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

All other assets are classified as non-current.

A liability is classified as current when it satisfies any ofthe following criteria:

- it is expected to be settled in the Company's normaloperating cycle;
- it is held primarily for the purpose of being traded;
- it is due to be settled within 12 months after thereporting date; or the Company does not have anunconditional right to defer settlement of the liabilityfor at least 12 months after the reporting date

Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

All other liabilities are classified as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

- **Goodwill**

  Goodwill arising on an acquisition of a business is carried at cost as established at the date of acquisition of the business less accumulated impairment losses, if any.

For the purposes of impairment testing, goodwill is allocated to each of the Group's cash-generating units (or groups of cash-generating units) that is expected to benefit from the synergies of the combination.

A cash-generating unit to which goodwill has been allocated is tested for impairment annually, or more frequently when there is indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognized directly in the consolidated Statement of Profit and Loss. An impairment loss recognized for goodwill is not reversed in subsequent periods. On disposal of the relevant cash-generating unit, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

- **Property, plant and Equipment**

  Property, plant and equipment are stated at acquisition cost net of tax / duty credit availed, less accumulated depreciation and accumulated impairment losses, if any. Properties in the course of construction are carried at cost, less any recognized impairment losses. All costs, including borrowing costs incurred up to the date the asset is ready for its intended use, is capitalized along with respective asset.

Depreciation is recognized based on the cost of assets less their residual values over their useful lives, using the straight-line method. The useful life of property, plant and equipment is considered based on life prescribed in schedule II to the Companies Act, 2013 for year 2024-25.

Asset	Useful Life
Office equipment	5 Years
Furniture	10 Years
Office Premise	60 Years
Vehicle	10 Years
Plant & Machinery	15 Years

- **Financial Instruments**
  Financial assets and financial liabilities are recognized when an entity becomes a party to the contractual provisions of the instruments.
  Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss.

- **Financial Assets**
  - **Classification**
    The Company classifies its financial assets in the following measurement categories:
    - Those to be measured subsequently at fair value (either through OCI, or through profit or loss), and
    - Those measured at amortized cost.
    - Those measured at carrying cost for equity instruments of subsidiaries and joint ventures.

  - **Initial recognition and measurement**
    All financial assets, are recognized initially at fair value

- **Financial liabilities and equity instruments**
  Classification as debt or equity
  Debt and equity instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

- **Equity instruments**
  An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs.

- **Financial liabilities**
  All financial liabilities are measured at amortized cost using the effective interest method or at FVTPL.

- **Financial liabilities at amortized cost**

  Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortized cost at the end of subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortized cost are determined based on the effective interest method. Interest expense that is not capitalized as part of costs of an asset is included in the 'Finance costs' line item.

Trade and other payables are recognized at the transaction cost, which is its fair value.

- **Fair value measurement**

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the financial asset or settle the financial liability takes place either:

• In the principal market, or

• In the absence of a principal market, in the most advantageous market

The principal or the most advantageous market must be accessible by the Company.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use.

- **Revenue recognition**

The Company has adopted Ind AS 115 from 1st April, 2019 and opted for modified retrospective application with the cumulative effect of initially applying this standard recognised at the date of initial application. The standard has been applied to all open contracts as on 1st April, 2019, and subsequent contracts with customers from that date.

Performance obligation:

The revenue is recognized on fulfillment of performance obligation.

- **Sale of products:**

The Company earns revenue primarily from sale of Pharmaceutical Products, Pharma Products. Payment for the sale is made as per the credit terms in the agreements with the customers. The credit period is generally short term, thus there is no significant financing component.

The Company's contracts with customers do not provide for any right to returns, refunds or similar obligations. The Company's obligation to repair or replace faulty products under standard warranty terms is recognized as a provision.

Revenue is recognized when the performance obligations are satisfied and the control of the product is transferred, being when the goods are delivered as per the relevant terms of the contract at which point in time the Company has a right to payment for the asset, customer has possession and legal title to the asset, customer bears significant risk and rewards of ownership and the customer has accepted the asset or the Company has objective evidence that all criteria for acceptance have been satisfied.

- **Borrowing costs**

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. Interest income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization.

- **Taxation**

  Tax on Income comprises current and deferred tax. It is recognized in statement of profit and loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive income.

- **Current tax**

  Tax on income for the current period is determined on the basis on estimated taxable income and tax credits computed in accordance with the provisions of the relevant tax laws and based on the expected outcome of assessments / appeals. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

- **Deferred tax**

  Deferred tax is recognized for the future tax consequences of deductible temporary differences between the carrying values of assets and liabilities and their respective tax bases at the reporting date, using the tax rates and laws that are enacted or substantively enacted as on reporting date. Deferred tax assets are recognized to the extent that it is probable that future taxable income will be available against which the deductible temporary differences can be utilized. Deferred tax relating to items recognized outside the statement of profit and loss is recognized outside the statement of profit and loss, either in other comprehensive income or directly in equity. The carrying amount of deferred tax assets is reviewed at each reporting date.

- **Earnings per share**
  The Company presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to the ordinary shareholders of the company by the weighted average number of ordinary shares outstanding during the period. Where ordinary shares are issued but not fully paid, they are treated in the calculation of basic earnings per share as a fraction of an ordinary share to the extent that they were entitled to participate in dividends during the period relative to a fully paid ordinary share. Diluted earnings per share is computed by dividing the net profit after tax by the weighted average number of equity sharesconsidered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented.

- **Foreign exchange transactions**
  Foreign exchange transactions are recorded using the exchange rates prevailing on the dates of the respective transactions. Exchange differences arising on foreign exchange transactions settled during the year are recognized in the statement of profit and loss for the year.

(In Lacs)

Particulars	**2025-26**	**2024-25**
Foreign Exchange Earning	668.36	404.95
Foreign Exchange Outgo	0	0

25. Notes on Accounts

- **Contingent Liabilities**
  There is no contingent liability as informed by management.

- **Capital Expenditure Commitments: Nil**

- **Related Party Transactions:-**
  As per Indian Accounting Standard (Ind AS -24) issued by the Institute of Chartered Accountants of India, the disclosures of transactions with the related parties are given below:
  List of related parties where control exists and related parties with whom transactions have taken place and relationships:

Sr. No.	Name	Relationship
1	Jayendra Mehta	Managing Director
2	Sarang B Pathak	Director
3	Jainil R Bhatt	Chief Financial Officer (Key Managerial Personnel)
4	Hemant A Parikh	Director (Resigned wef 17.03.2026)
5	Rina Kumari	Independent Director
6	Hitesh Rijwani	Independent Director
7	Siddhi Shah	Company Secretary (Resigned wef 26.09.2025)
8	Parth Hemant Parikh	Promoter of the Company
9	Parth Hemant Parikh	Promoter of the Company and also provides an unsecured loan to Vivanza Biosciences Limited
10	Ravina Aditya parikh	Promoter of the Company
11	Ravina Aditya parikh	Promoter of the Company and also provides an unsecured loan to Vivanza Biosciences Limited
12	Tarla Amrishbhai Parikh	Promoter of the Company
13	Tarla Amrishbhai Parikh	Promoter of the Company and also provides an unsecured loan to Vivanza Biosciences Limited
14	Vivanza Lifesciences Private Limited	Wholly Owned Subsidiary
15	Vivanza Lifesciences Private Limited	Mr. Hemant A. Parikh is a Director of the Company has provides an unsecured loan to Vivanza Lifesciences Private limited
16	Viva Energy Fertilizers Private Limited	Mr. Hemant A Parikh Director of the Company is Director in Viva Energy Fertilizers Private Limited
17	Viva Energy Fertilizers Private Limited	Mr. Hemant A Parikh Director of the Company has given an unsecured loan to this company.
18	Vitaaglobal Bioscience Private Limited	Mr. Hemant A Parikh Director of the Company are Director in Vitaaglobal Bioscience Private Limited and also provides and unsecured loan to this company.
19	Vital I.P. Private Limited (Formerly known as Vital Interiors &Furnitures Private Limited) VITAL I.P. Private Limited	Mr. Hemant A Parikh Director of the Company are Director of vital I.P. Private limited (Formerly known as Vital Interiors &Furnitures Private Limited)

20	Vital I.P. Private Limited (Formerly known as Vital Interiors &Furnitures Private Limited) VITAL I.P. Private Limited	Mr. Hemant A Parikh Director of the Company has provided an unsecured loan to this Company
21	VipronovaLifescience Private Limited	Mr. Hemant A Parikh and Parth Hemant Parikh Director of the Company was a Director in Vipronova Lifescience Private Limited
22	Vitale Beverages Private Limited	Mr. Hemant A Parikh Director of the Company has provides an unsecured loan to this Company
23	Vitale Beverages Private Limited	Mr. Hemant A Parikh Director of the Company are Director in Vitale Beverages Private Limited
24	CKIM Pharma LLP	Joint Venture LLP and Mr. Hemant Parikh is a Designated Partner in this LLP
25	Viva Surbhi Biotech LLP	Mr. Hemant A. Parikh is a Director in Viva Surbhi Biotech LLP
26	Vaishali Lifecare Private Limited	Mr. Hemant A. Parikh Director of the Company has given an unsecured loan to this Company.
27	Winfra Green Projects Private Limited	Mr. Hemant A. Parikh Director of the Company has given an unsecured loan to this Company.
28	Winfra Green Projects Private Limited	Mr. Parth Parikh Promoter of the Company has given an unsecured loan to this Company.
29	Meghdhanush Drones and Agro Technologies Private Limited	Mr. Parth Parikh Promoter of the Company has given an unsecured loan to this Company.
30	Winfra Green Projects Private Limited	Ms. Ravina Aditya Parikh Promoter of the Company has given an unsecured loan to this Company.
31	Winfra Green Projects Private Limited	Ms. Tarla Parikh Promoter of the Company has given an unsecured loan to this Company.
32	Vital Intelligence Technology Private Limited	Mr. Parth Parikh Promoter of the Company has given an unsecured loan to this Company.

- **Transactions with Related Parties**

  Transactions that have taken place during the period April 1, 2025to March 31, 2026 with related parties by the company stated below :

Sr. No.	Name	Nature of the Transaction	Amount Outstanding
1	Vivanza Lifesciences Pvt. Ltd.	Loan Granted	1.21
		Loan Recovered	19.92
		Closing Balance	NIL
		Purchase	260.85

		Sales	110.34
2	Jainil Bhatt	Directors Remuneration Payable	3.3
		Directors Remuneration Paid	3.65
		Closing Balance	NIL
		Loan Granted	0
		Loan Recovered	0.33
		Closing Balance	0.8
3	Rina Kumari	Opening Balance	0
		Salary Payable	0.52
		Paid	0.52
		Closing Balance	0
4	Hitesh Rijwani	Opening Balance	0
		Salary Payable	0.4
		Paid	0.4
		Closing Balance	0
5	Siddhi Shah	Opening Balance	0.44
		Salary Payable	4.51
		Paid	4.95
		Closing Balance	0
6	Parth Hemant Parikh	Opening Balance	20
		Loan Given	0
		Loan Repayment	0
		Closing Balance	20
7	Ravina Aditya Parikh	Opening Balance	20
		Loan Given	0
		Loan Repayment	0
		Closing Balance	20
8	Tarla Amrish Parikh	Opening Balance	20
		Loan Given	0

		Loan Repayment	0
		Closing Balance	20
9	Vitaaglobal Bioscience Private Limited	Sales	NIL
		Purchase	NIL
		Loan Granted	NIL
		Loan Recovered	NIL
		Closing Balance	102.9
10	Loan Taken By Vivanza Bioscience from	Loan Taken	267.47
	Winfra Green Projects Private Limited	Loan Paid	87.22
		Closing Balance	524.6
11	Viva Surbhi Biotech LLP	Opening Balance	2
		Loan Given	0
		Loan Repayment	0
		Closing Balance	2
12	Vaishali Lifecare Private Limited	Opening Balance	6.39
		Loan Given	0
		Loan Repayment	0
		Closing Balance	6.39
14	Vivanza Lifesciences Pvt. Ltd.	Loan Granted	1.21
		Loan Recovered	19.92
		Closing Balance	NIL
		Purchase	260.85
		Sales	110.34
15	Loan Takn by Vivanza Life sciences Pvt Ltd	Loan Taken	24.86
	from Winfra Green Projects Private Limited	Loan Paid	13.25
		Closing Balance	182.8

- **Payment to the Auditors**

Particulars	2025-26	2024-25
Audit Fees	0.80	0.55
Company Matter	0	0
Income Tax Fees	0	0
Others	0	0
Total	**0.80**	**0.55**

- **Earnings per Share:-**

  The earning considered in ascertaining the company's EPS comprises the profit available for shareholders i.e. profit after tax and statutory/regulatory appropriations. The number of shares used in computing Basic EPS is the weighted average number of shares outstanding during the year as per the guidelines of IndAS-33.

Particulars	31-03-2026	31-03-2025
Net Profit Attributable to share holders	39.44	(67.41)
Weighted average number of equity shares (Nos.)	400.00	400.00
Basic and diluted earnings per share (Rs.)	0.10	(0.17)
Nominal value of equity share (Rs.)	1	1

- **Capital Management**

  The Company manages its capital to ensure that entities in the Company will be able to continue as going concerns while maximizing the return to stakeholders through the optimization of the debt and equity balance. The capital structure of the Company consists of net debt (borrowings offset by cash and bank balances) and total equity of the Company.

Particulars	As at	As at
	31st March, 2026	**31st March 2025**
Total equity attributable to the equity share holders of the company	400.00	400.00
As percentage of total capital	28.31%	31.91%
Current loans and borrowings	931.46	531.73
Non-current loans and borrowings	87.72	333.49
Total loans and borrowings	**1,019.18**	**865.22**
Cash and cash equivalents	6.53	11.69
Net loans & borrowings	1012.65	853.53
As a percentage of total capital	71.69%	68.09%
Total capital (loans and borrowings and equity)	**1412.65**	**1253.53**

- **Fair Value measurements**

Financial instruments by category

Particulars	As at 31st March, 2026			As at 31st March, 2025		
	Amortized Cost	FVTPL	FVTOCI	Amortized Cost	FVTPL	FVTOCI
Financial Asset						
Investment		0.25	-		0.25	-
Other Non-Current Assets	-	59.33	-	-	59.33	-
Trade receivables	-	1238.33		-	805.93	
Non Current Loans		0.00	-		113.82	-
Cash & Cash Equivalents	-	6.53	-	-	11.69	-
Current Loans	-	270.99	-	-	164.36	-
Total Financial Asset	-	**1575.44**	**-**	-	**1155.38**	**-**
	-			**-**		
Financial Liabilities						
Non-Current Borrowings		87.72	-		333.49	-
Trade Payables	-	719.41	-	-	261.81	-
Current Borrowing	-	931.46	-	-	531.73	-
Total Financial Liabilities	-	**1738.59**	**-**	-	**1127.03**	**-**

***** Excluding investments in subsidiaries, joint control entities and associates measured at cost in accordance with Ind AS-27

Fair value hierarchy

The following section explains the judgments and estimates made in determining the fair values of the financial instruments that are recognized and measured at fair value through profit or loss. To provide an indication about the reliability of the inputs used in determining fair value, the Company has classified its financial investments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

B. Fair value hierarchy for assets

Financial assets measured at fair value at March 31, 2026

	Level 1	Level 2	Level 3	Total
Financial Assets				
Investment	0.25		-	0.25

Financial assets measured at fair value at March 31, 2025

	Level 1	Level 2	Level 3	Total
Financial Assets Investment	0.25	-	-	0.25

Notes:

Level 1 hierarchy includes financial instruments measured using quoted prices (unadjusted) in active market for identical assets that the entity can access at the measurement date. This represents mutual funds that have price quoted by the respective mutual fund houses and are valued using the closing Net asset value (NAV).

Level 2 hierarchy includes the fair value of financial instruments measured using quoted prices for identical or similar assets in markets that are not active.

Level 3 if one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted compound instruments.

There are no transfers between any of these levels during the year. The Company's policy is to recognize transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.

C. Fair value of financial assets and liabilities measured at amortized cost

The Management has assessed that fair value of loans, trade receivables, cash and cash equivalents, other bank balances, other financial assets and trade payables approximate their carrying amounts largely due to their short term nature. Difference between carrying amount of Bank deposits, other financial assets, borrowings and other financial liabilities subsequently measured at amortized cost is not significant in each of the years presented.

For financial assets and liabilities that are measured at fair value, the carrying amounts are equal to the fair values.

- **Financial risk management**

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The board has established the Audit Committee, which is responsible for developing and monitoring the Company's risk management policies. The Committee holds regular meetings and report to board on itsactivities. The Company's risk management policies are established to identify and analyses the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

This note explains the sources of risk which the entity is exposed to and how the entity manages the risk.

Risk	Exposure arising from	Measurement	Management of risk
Credit Risk	Cash and cash equivalents, trade receivables, Financial assets measured at amortized cost.	Aging analysis	Diversification of funds to bank deposits, Liquid funds and Regular monitoring of credit limits
Liquidity Risk	Borrowings and other liabilities	Rolling cash flow forecasts	Availability of surplus cash, committed credit lines and borrowing facilities

(a) Credit risk

Credit risk is the risk of financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The company is exposed to the credit risk from its trade receivables, unbilled revenue, investments, cash and cash equivalents, bank deposits and other financial assets. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses in financial assets.

Trade Receivables

Trade receivables comprise a widespread customer base. Management evaluates credit risk relating to customers on an on-going basis. If customers are independently rated, these ratings are used. Otherwise, if there is no independent rating, risk control assesses the credit quality of the customer, taking into account its financial position, past experience and other factors

For trade receivables, provision is provided by the company as per the below mentioned policy:

Particulars	Gross Carrying Amount	**Expected credit losses rate (%)**	Expected Credit Losses	Carrying amount of Trade Receivable
Considered for Goods				
0-6 Months	515.19	0	0	515.19
More than 6 Months	723.14	0	0	723.14
Total	**1238.33**	**0**	**0**	**1238.33**

(b) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

Liquidity Table

The Company's remaining contractual maturity for its non-derivative financial liabilities with agreed repayment periods is given below. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the Company can be required to pay. The tables include both interest and principal cash flows. The contractual maturity is based on the earliest date on which the Company may be required to pay.

As at March 31, 2026

Financial Liabilities	**Payable within 0 to 12 months**	**More than 12 months**	**Total**
Non-current financial liabilities	-	87.72	87.72
Borrowings			
Current financial liabilities			
Borrowings	931.46	-	931.46
Trade Payables	691.85	27.55	719.41
Other Financial Liability		-	
Total financial liabilities	**1650.86**	**87.72**	**1738.58**

As at March 31, 2025

Financial Liabilities	Payable within 0 to 12 months	More than 12 months	Total
Non-current financial liabilities			
Borrowings	-	333.48	333.48
Current financial liabilities			
Borrowings	531.73	-	531.73
Trade Payables	90.34	171.47	261.81
Other Financial Liability		-	
Total financial liabilities	**793.54**	**333.48**	**1127.03**

(C) Market Risk

Market risk is the risk arising from changes in market prices – such as foreign exchange rates and interest rates – will affect the Company's income or the value of its holdings of financial instruments. The Company is exposed to market risk primarily related to interest rate risk and the market value of the investments. Thus, the exposure to market risk is a function of investing and borrowing activities

- **Interest rate risk**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

Most of the Company's borrowings are on a floating rate of interest. The Company has exposure to interest rate risk, arising principally on changes in Marginal Cost of Funds based Lending Rate (MCLR). The Company uses a mix of interest rate sensitive financial instruments to manage the liquidity and fund requirements for its day to day operations like short term credit lines besides internal accruals.

The exposures of the Company's financial assets / liabilities at the end of the reporting period are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Floating Rate Borrowings	136.62	187.38

(D) Price Risk Exposure

The Company's exposure to securities price risk arises from investments held in mutual funds and classified in the balance sheet at fair value through profit or loss. To manage its price risk arising from such investments, the Company diversifies its portfolio. Further these are all debt base securities for which the exposure is primarily on account of interest rate risk. Quotes (NAV) of these investments are available from the mutual fund houses. Profit for the year would increase/decrease as a result of gains/losses on these securities classified as at fair value through profit or loss.

➢ **<u>Others</u>**

- Balance Sheet is still carrying Opening Balance of "P & P Expenses and issue related expenses" of Rs. 3.66 lakhs /- as "Other Current Assets", which in our opinion needs to be written off in Five Financial Years proportionately. And Due to the same expense is under stated in profit & loss account.
- Balance of sundry debtors and creditors, loans and advances accepted and given in the balance sheet are subject to confirmation.
- As informed by the management that the loans are interest free, which in our opinion is violation of Section 186 (7) of the Companies Act, 2013.
- Above Disclosure is made after taking into account the principle of materiality.
- In the events of non-availability of suitable supporting vouchers, Directors have given us certificate that these expenses are incurred mainly for the business activities of the company.

- The previous year's figures have been reworked, regrouped, rearranged and reclassified wherever necessary. Amounts and other disclosures for the preceding year are included as an integral part of the current year financial statements and are to be read in relation to the amounts and other disclosures relating to the current year.

- **<u>Financial Ratios for the Financial Year 2025-26:</u>**

Sr.	Financial Ratios	Particulars	Numerator / Denominator taken	As at 31st March, 2026	As at 31st March, 2025	% change in Ratio	Remark - Any change in the ratio by more than 25% as compared to the preceding year.
1	Current Ratio (CA/CL)	Ratio		1.13	1.35	(16.42)	Within the Limit
		Numerator	Current Assets	1,905.49	1238.43		
		Denominator	Current Liabilities	1,685.15	915.42		
2	Debt-Equity Ratio	Ratio		2.34	2.18	7.14	Within The Limit
		Numerator	Total Borrowings (Including Current Maturities of Long term borrowing)	1,019.18	865.22		
		Denominator	Total Equity	435.85	396.41		
3	Debt Service Coverage Ratio	Ratio		3.02	(0.85)	303	1.Due to Profit in current year.
		Numerator	Profit before exceptional items, taxes, Depreciation and Amortisation Expenses and Interest Expenses	84.45	(30.03)		

		Denominator	1. Interest on Loan 2. Current Maturities of Long term loan (Installments)	27.92	35.14		
4	**Return on Equity Ratio**	**Ratio**		**9.48**	**(15.67)**	**160.50**	1.Due to Profit in current year.
		Numerator	Profit for the year after tax	39.44	(67.41)		
		Denominator	Average Total Equity	416.13	430.12		
5	**Inventory Turnover Ratio**	**Ratio**		**39.36**	**3.20**	**1,131.98**	1.Due to Increase in cogs.
		Numerator	Cost of Goods Sold	11,442.61	682.06		
		Denominator	Average Inventories	290.69	213.47		
6	**Trade Receivables Turnover Ratio**	**Ratio**		**11.34**	**0.76**	**1,396.99**	1.Due to Increase in revenue from operations.
		Numerator	Revenue from Operations	11,591.06	742.33		
		Denominator	Average Trade receivables	1,022.13	979.93		
7	**Trade Payables Turnover Ratio**	**Ratio**		**23.59**	**1.30**	**1,708.38**	1.Due to Increases in Purchases.
		Numerator	Total Purchases	11,571.38	707.74		
		Denominator	Average Trade payables (including advance from customer)	490.61	542.64		
8	**Net Capital Turnover Ratio**	**Ratio**		**52.61**	**2.30**	**2,189.05**	1.Due to decrease in
		Numerator	Revenue from Operations	11,591.06	742.33		

		Denominator	Average Working Capital	220.33	323.00		Revenue from Operations.
9	**Net Profit Ratio (PAT/Revenue)**	**Ratio**		**0.34**	**(9.08)**	**103.74**	1.Due to Profit in current year.
		Numerator	Profit after Taxes	39.44	(67.41)		
		Denominator	Revenue from Customers	11,591.06	742.33		
10	**Return on Capital employed**	**Ratio**		**18.88**	**(7.93)**	**338.05**	1.Due to Profit in current year.
		Numerator	Profit before tax and Interest expense	82.30	(31.43)		
		Denominator	Capital Employed	435.85	396.41		
11	**Return on Investment**	**Ratio**		**0.00**	**0.00**	**0.00**	Within the Limit
		Numerator	Income From Investment	0.00	0.00		
		Denominator	Cost of Investment	0.25	0.25		

For, Vivanza Biosciences Limited

For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

Jayendra Mehta
Managing Director
DIN:08210602

Sarang Pathak
Director
DIN: 02663344

Jainil Bhatt
CFO

CA Shivam Soni
Proprietor
Memberships No. 178351
UDIN: 26178351OXOEJD2109

Place: Ahmedabad
Date:07TH May, 2026

Notes :

Notes :

BOOK-POST

To,

If undelivered please retrun to:

VIVANZA™

BIOSCIENCES LTD.

Corporate Office : 403/TF, Sarthik-II, Opp. Rajpath Club, S.G.Highway, Bodakdev, Ahmedabad-380054. INDIA.
Tel. : +91 79 26870952/54.
Email: info@vivanzabiosciences.com
www.vivanzabiosciences.com